<Version><xmlsource>This XML content was developed by AHRQ's contractor ECRI Institute for the National Guideline Clearinghouse (NGC).</xmlsource><Section SecID="390" OrdBy="100" Name="General"><Field FieldID="161" OrdBy="105" ID="391" Name="Guideline Title" Type="text"><FieldValue Value="&lt;div class=&quot;content_title&quot;&gt;Prevention of vascular and metabolic disease. In: Guidelines for preventive activities in general practice, 8th edition.&lt;/div&gt;" /></Field><Field FieldID="97" OrdBy="110" ID="392" Name="Bibliographic Source(s)" Type="citation"><FieldValue Value="&lt;table&gt;&lt;tr&gt;&lt;td&gt;Prevention of vascular and metabolic disease. In: Guidelines for preventive activities in general practice, 8th edition. East Melbourne (Australia): Royal Australian College of General Practitioners; 2012. p. 50-9.&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;" /></Field><Field FieldID="120" OrdBy="115" ID="393" Name="Guideline Status" Type="text"><FieldValue Value="&lt;div class=&quot;content_para&quot;&gt;&lt;p&gt;This is the current release of the guideline.&lt;/p&gt;&lt;/div&gt;" /></Field><Field Name ="UMLS Concepts"><FieldValue Value="ICD9CM: Cardiovascular disease, unspecified  (429.2); Complications affecting other specified body systems, not elsewhere classified, hypertension  (997.91); Diabetes mellitus without mention of complication, type II or unspecified type, not stated as uncontrolled  (250.00); Loss of weight  (783.21); Unspecified disorder of lipoid metabolism  (272.9)"/><FieldValue Value="MSH: Albuminuria ; Antihypertensive Agents ; Auscultation ; Blood Chemical Analysis ; Blood Glucose ; Blood Pressure Determination ; Cardiovascular Diseases ; Diabetes Mellitus, Type 2 ; Diabetes, Gestational ; Diet, Fat-Restricted ; Exercise ; General Practice ; Glomerular Filtration Rate ; Glucose Tolerance Test ; Health Promotion ; Hemoglobin A, Glycosylated ; Hydroxymethylglutaryl-CoA Reductase Inhibitors ; Hyperlipidemias ; Hypertension ; Ischemic Attack, Transient ; Kidney Diseases ; Kidney Function Tests ; Life Style ; Lipid Metabolism Disorders ; Motor Activity ; Preconception Care ; Prediabetic State ; Preventive Health Services ; Primary Health Care ; Risk Assessment ; Stroke ; Ultrasonography, Doppler, Duplex ; Weight Loss "/><FieldValue Value="MTH: Albumin To Creatinine Protein Ratio Measurement ; Albuminuria ; Antihypertensive Agents ; Auscultation ; Blood Chemical Analysis ; Blood Glucose ; Blood glucose measurement ; Blood pressure determination ; Body Weight decreased ; Cardiovascular Diseases ; Carotid bruit ; Cerebrovascular accident ; Diabetes Mellitus, Non-Insulin-Dependent ; Diet education ; Exercise ; Fat-Restricted Diet ; general practice (field) ; Gestational Diabetes ; Glomerular Filtration Rate ; Glucose Tolerance Test ; Glycosylated hemoglobin A ; Hemoglobin A1c measurement ; Hydroxymethylglutaryl-CoA Reductase Inhibitors ; Hyperlipidemia ; Hypertensive disease ; Kidney Diseases ; Kidney Function Tests ; Life Style ; Lipid Metabolism Disorders ; Physical activity ; Prediabetes syndrome ; Primary Health Care ; Risk Assessment ; Transient Ischemic Attack "/><FieldValue Value="SNOMEDCT_US: Albumin/creatinine ratio measurement  (250745003); Albuminuria  (274769005); Assessment for risk of cardiovascular disease  (441829007); At risk of diabetes mellitus  (161641009); Auscultation  (129436005); Auscultation  (37931006); Blood chemistry  (166312007); Blood pressure taking  (46973005); Carotid bruit  (419642000); Cerebrovascular accident  (230690007); Diet education  (11816003); Disorder of cardiovascular system  (49601007); Disorder of lipid metabolism  (267431006); Duplex ultrasound  (312236008); Exercise  (183301007); Exercise  (256235009); Exercise  (61686008); Fasting lipid profile  (252150008); General medicine  (394802001); Gestational diabetes mellitus  (11687002); Glomerular filtration rate  (80274001); Glucose measurement, blood  (33747003); Glucose tolerance test  (113076002); Glycosylated hemoglobin A  (33601001); Health promotion  (171434007); Hemoglobin A1c measurement  (43396009); HMG-CoA reductase inhibitor  (372912004); HMG-CoA reductase inhibitor  (96302009); Hyperlipidemia  (55822004); Hypertensive disorder  (38341003); Hypotensive agent  (1182007); Hypotensive agent  (372586001); Kidney disease  (90708001); Life style  (134436002); Life style  (60134006); Low fat diet  (16208003); Low fat diet  (436861000124104); Physical activity  (48761009); Physical activity  (68130003); Preconception care  (429070000); Renal function study  (44277000); Risk assessment  (225338004); Stroke risk  (135877001); Transient cerebral ischemia  (266257000); Type 2 diabetes mellitus  (44054006); Weight decreased  (161832001); Weight decreased  (262285001); Weight decreased  (89362005)"/><FieldValue Value="SPN: SYSTEM, IMAGING, PULSED DOPPLER, ULTRASONIC "/><FieldValue Value="UMD: Scanning Systems, Ultrasonic  (14-278); Scanning Systems, Ultrasonic, Vascular  (15-957)"/></Field></Section><Section SecID="396" OrdBy="300" Name="Scope"><Field FieldID="140" OrdBy="305" ID="397" Name="Disease/Condition(s)" Type="text"><FieldValue Value="&lt;ul style=&quot;list-style-type: disc;&quot;&gt;&#xD;&#xA;    &lt;li&gt;Cardiovascular disease (CVD) &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Hypertension &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Hyperlipidaemia &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Type 2 diabetes &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Stroke &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Kidney disease &lt;/li&gt;&#xD;&#xA;&lt;/ul&gt;" /></Field><Field FieldID="103" OrdBy="310" ID="398" Name="Guideline Category" Type="picklist-many"><FieldValue Value="Counseling" /><FieldValue Value="Management" /><FieldValue Value="Prevention" /><FieldValue Value="Risk Assessment" /><FieldValue Value="Screening" /><FieldValue Value="Treatment" /></Field><Field FieldID="113" OrdBy="315" ID="399" Name="Clinical Specialty" Type="picklist-many"><FieldValue Value="Cardiology" /><FieldValue Value="Endocrinology" /><FieldValue Value="Family Practice" /><FieldValue Value="Geriatrics" /><FieldValue Value="Internal Medicine" /><FieldValue Value="Nephrology" /><FieldValue Value="Preventive Medicine" /></Field><Field FieldID="114" OrdBy="320" ID="400" Name="Intended Users" Type="picklist-many"><FieldValue Value="Advanced Practice Nurses" /><FieldValue Value="Nurses" /><FieldValue Value="Physician Assistants" /><FieldValue Value="Physicians" /><FieldValue Value="Public Health Departments" /></Field><Field FieldID="129" OrdBy="325" ID="401" Name="Guideline Objective(s)" Type="text"><FieldValue Value="&lt;ul style=&quot;list-style-type: disc;&quot;&gt;&#xD;&#xA;    &lt;li&gt;To facilitate evidence-based preventive activities for prevention of vascular and metabolic disease in primary care &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;To provide a comprehensive and concise set of recommendations for patients in general practice with additional information about tailoring risk and need &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;To provide the evidence base for which primary healthcare resources can be used efficiently and effectively while providing a rational basis to ensure the best use of time and resources in general practice &lt;/li&gt;&#xD;&#xA;&lt;/ul&gt;" /></Field><Field FieldID="132" OrdBy="330" ID="402" Name="Target Population" Type="text"><FieldValue Value="&lt;div class=&quot;content_para&quot;&gt;&lt;p&gt;Adult Australian population&lt;/p&gt;&#xD;&#xA;&lt;p class=&quot;Note&quot;&gt;&lt;strong&gt;Note&lt;/strong&gt;: See the &quot;Major Recommendations&quot; field for age ranges associated with specific conditions.&lt;/p&gt;&lt;/div&gt;" /></Field><Field FieldID="133" OrdBy="335" ID="403" Name="Interventions and Practices Considered" Type="text"><FieldValue Value="&lt;ol style=&quot;list-style-type: decimal;&quot; start=&quot;1&quot;&gt;&#xD;&#xA;    &lt;li&gt;Calculation and assessment of absolute cardiovascular disease (CVD) risk &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Measurement of blood pressure &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Providing lifestyle advice and education about hypertension and antihypertensive pharmacotherapy if necessary &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Measurement of fasting blood lipids &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Dietary and other lifestyle advice about hyperlipidaemia and lipid-lowering therapy if necessary &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Screening for type 2 diabetes&#xD;&#xA;    &lt;ul style=&quot;list-style-type: disc;&quot;&gt;&#xD;&#xA;        &lt;li&gt;Use of Australian Type 2 Diabetes Risk Assessment Tool (AUSDRISK) scoring to determine risk &lt;/li&gt;&#xD;&#xA;        &lt;li&gt;Fasting blood sugar &lt;/li&gt;&#xD;&#xA;        &lt;li&gt;Oral glucose tolerance test &lt;/li&gt;&#xD;&#xA;        &lt;li&gt;Glycated haemoglobin (HbA1c) &lt;/li&gt;&#xD;&#xA;    &lt;/ul&gt;&#xD;&#xA;    &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Increased physical activity and/or weight loss, dietary advice for patients with pre-diabetes &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Preconception advice to women with a history of gestational diabetes &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Being alert to symptoms of transient ischaemic attacks (TIAs) &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Auscultation for carotid bruit (not recommended for general population as screening tool for stroke) &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Duplex ultrasonography as a screening tool for stroke &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Risk assessment for stroke using age, blood pressure, clinical features, duration, diabetes (ABCD2) tool &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Screening high risk patients for kidney disease&#xD;&#xA;    &lt;ul style=&quot;list-style-type: disc;&quot;&gt;&#xD;&#xA;        &lt;li&gt;Albuminuria with calculation of albumin:creatinine ratio (ACR) &lt;/li&gt;&#xD;&#xA;        &lt;li&gt;Glomerular filtration rate (GFR) &lt;/li&gt;&#xD;&#xA;    &lt;/ul&gt;&#xD;&#xA;    &lt;/li&gt;&#xD;&#xA;&lt;/ol&gt;" /></Field><Field FieldID="134" OrdBy="340" ID="404" Name="Major Outcomes Considered" Type="text"><FieldValue Value="&lt;div class=&quot;content_para&quot;&gt;&lt;p&gt;Risk for and incidence of cardiovascular and metabolic diseases&lt;/p&gt;&lt;/div&gt;" /></Field></Section><Section SecID="405" OrdBy="400" Name="Methodology"><Field FieldID="109" OrdBy="405" ID="406" Name="Methods Used to Collect/Select the Evidence" Type="picklist-many"><FieldValue Value="Hand-searches of Published Literature (Primary Sources)" /><FieldValue Value="Hand-searches of Published Literature (Secondary Sources)" /><FieldValue Value="Searches of Electronic Databases" /></Field><Field FieldID="135" OrdBy="410" ID="407" Name="Description of Methods Used to Collect/Select the Evidence" Type="text"><FieldValue Value="&lt;div class=&quot;content_para&quot;&gt;&lt;p&gt;&lt;strong&gt;Sources of Recommendations&lt;/strong&gt;&lt;/p&gt;&#xD;&#xA;&lt;p&gt;The recommendations in these guidelines are based on current, evidence-based guidelines for preventive activities. The Taskforce focused on those most relevant to Australian general practice. Usually this means that the recommendations are based on Australian guidelines such as those endorsed by the National Health and Medical Research Council (NHMRC).&lt;/p&gt;&#xD;&#xA;&lt;p&gt;In cases where these are not available or recent, other Australian sources have been used, such as guidelines from the Heart Foundation, Canadian or United States preventive guidelines, or the results of systematic reviews. References to support these recommendations are listed. However, particular references may relate to only part of the recommendation (e.g., only relating to one of the high-risk groups listed) and other references in the section may have been considered in formulating the overall recommendation.&lt;/p&gt;&lt;/div&gt;" /></Field><Field FieldID="136" OrdBy="415" ID="408" Name="Number of Source Documents" Type="text"><FieldValue Value="&lt;div class=&quot;content_para&quot;&gt;&lt;p&gt;Not stated&lt;/p&gt;&lt;/div&gt;" /></Field><Field FieldID="115" OrdBy="420" ID="409" Name="Methods Used to Assess the Quality and Strength of the Evidence" Type="picklist-choice"><FieldValue Value="Weighting According to a Rating Scheme (Scheme Given)" /></Field><Field FieldID="149" OrdBy="425" ID="410" Name="Rating Scheme for the Strength of the Evidence" Type="text"><FieldValue Value="&lt;div class=&quot;content_para&quot;&gt;&lt;p&gt;&lt;strong&gt;Levels of Evidence&lt;/strong&gt;&lt;/p&gt;&#xD;&#xA;&lt;table border=&quot;1&quot; cellspacing=&quot;1&quot; cellpadding=&quot;3&quot; summary=&quot;Table: Levels of Evidence&quot;&gt;&#xD;&#xA;    &lt;thead&gt;&#xD;&#xA;        &lt;tr&gt;&#xD;&#xA;            &lt;th valign=&quot;top&quot;&gt;Level&lt;/th&gt;&#xD;&#xA;            &lt;th valign=&quot;top&quot;&gt;Explanation&lt;/th&gt;&#xD;&#xA;        &lt;/tr&gt;&#xD;&#xA;    &lt;/thead&gt;&#xD;&#xA;    &lt;tbody&gt;&#xD;&#xA;        &lt;tr&gt;&#xD;&#xA;            &lt;td valign=&quot;top&quot;&gt;I&lt;/td&gt;&#xD;&#xA;            &lt;td valign=&quot;top&quot;&gt;Evidence obtained from a systematic review of level II studies&lt;/td&gt;&#xD;&#xA;        &lt;/tr&gt;&#xD;&#xA;        &lt;tr&gt;&#xD;&#xA;            &lt;td valign=&quot;top&quot;&gt;II&lt;/td&gt;&#xD;&#xA;            &lt;td valign=&quot;top&quot;&gt;Evidence obtained from a randomised controlled trial (RCT)&lt;/td&gt;&#xD;&#xA;        &lt;/tr&gt;&#xD;&#xA;        &lt;tr&gt;&#xD;&#xA;            &lt;td valign=&quot;top&quot;&gt;III&amp;ndash;1&lt;/td&gt;&#xD;&#xA;            &lt;td valign=&quot;top&quot;&gt;Evidence obtained from a pseudo-randomised controlled trial (i.e., alternate allocation or some other method)&lt;/td&gt;&#xD;&#xA;        &lt;/tr&gt;&#xD;&#xA;        &lt;tr&gt;&#xD;&#xA;            &lt;td valign=&quot;top&quot;&gt;III&amp;ndash;2&lt;/td&gt;&#xD;&#xA;            &lt;td valign=&quot;top&quot;&gt;Evidence obtained from a comparative study with concurrent controls:&#xD;&#xA;            &lt;ul style=&quot;list-style-type: disc;&quot;&gt;&#xD;&#xA;                &lt;li&gt;Non-randomised, experimental trial &lt;/li&gt;&#xD;&#xA;                &lt;li&gt;Cohort study &lt;/li&gt;&#xD;&#xA;                &lt;li&gt;Case&amp;ndash;control study &lt;/li&gt;&#xD;&#xA;                &lt;li&gt;Interrupted time series with a control group &lt;/li&gt;&#xD;&#xA;            &lt;/ul&gt;&#xD;&#xA;            &lt;/td&gt;&#xD;&#xA;        &lt;/tr&gt;&#xD;&#xA;        &lt;tr&gt;&#xD;&#xA;            &lt;td valign=&quot;top&quot;&gt;III&amp;ndash;3&lt;/td&gt;&#xD;&#xA;            &lt;td valign=&quot;top&quot;&gt;Evidence obtained from a comparative study without concurrent controls:&#xD;&#xA;            &lt;ul style=&quot;list-style-type: disc;&quot;&gt;&#xD;&#xA;                &lt;li&gt;Historical control study &lt;/li&gt;&#xD;&#xA;                &lt;li&gt;Two or more single arm study &lt;/li&gt;&#xD;&#xA;                &lt;li&gt;Interrupted time series without a parallel control group &lt;/li&gt;&#xD;&#xA;            &lt;/ul&gt;&#xD;&#xA;            &lt;/td&gt;&#xD;&#xA;        &lt;/tr&gt;&#xD;&#xA;        &lt;tr&gt;&#xD;&#xA;            &lt;td valign=&quot;top&quot;&gt;IV&lt;/td&gt;&#xD;&#xA;            &lt;td valign=&quot;top&quot;&gt;Case series with either post-test or pre-test/post-test outcomes&lt;/td&gt;&#xD;&#xA;        &lt;/tr&gt;&#xD;&#xA;        &lt;tr&gt;&#xD;&#xA;            &lt;td valign=&quot;top&quot;&gt;Practice Point&lt;/td&gt;&#xD;&#xA;            &lt;td valign=&quot;top&quot;&gt;Opinions of respected authorities, based on clinical experience, descriptive studies or reports of expert committees&lt;/td&gt;&#xD;&#xA;        &lt;/tr&gt;&#xD;&#xA;    &lt;/tbody&gt;&#xD;&#xA;&lt;/table&gt;&lt;/div&gt;" /></Field><Field FieldID="116" OrdBy="430" ID="411" Name="Methods Used to Analyze the Evidence" Type="picklist-many"><FieldValue Value="Review of Published Meta-Analyses" /><FieldValue Value="Systematic Review" /></Field><Field FieldID="150" OrdBy="435" ID="412" Name="Description of the Methods Used to Analyze the Evidence" Type="text"><FieldValue Value="&lt;div class=&quot;content_para&quot;&gt;&lt;p&gt;Not stated&lt;/p&gt;&lt;/div&gt;" /></Field><Field FieldID="112" OrdBy="440" ID="413" Name="Methods Used to Formulate the Recommendations" Type="picklist-choice"><FieldValue Value="Expert Consensus" /></Field><Field FieldID="145" OrdBy="445" ID="414" Name="Description of Methods Used to Formulate the Recommendations" Type="text"><FieldValue Value="&lt;div class=&quot;content_para&quot;&gt;&lt;p&gt;These &lt;em&gt;Guidelines for preventive activities in general practice&lt;/em&gt;, 8th edition, have been developed by a taskforce of general practitioners (GPs) and experts to ensure that the content is the most valuable and useful for GPs and their teams. The guidelines provide an easy, practical and succinct resource. The content broadly conforms to the highest evidence-based standards according to the principles underlying the Appraisal of Guidelines Research and Evaluation.&lt;/p&gt;&#xD;&#xA;&lt;p&gt;The dimensions addressed are:&lt;/p&gt;&#xD;&#xA;&lt;ul style=&quot;list-style-type: disc;&quot;&gt;&#xD;&#xA;    &lt;li&gt;Scope and purpose &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Clarity of presentation &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Rigour of development &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Stakeholder involvement &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Applicability &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Editorial independence &lt;/li&gt;&#xD;&#xA;&lt;/ul&gt;&#xD;&#xA;&lt;p&gt;The Red Book maintains developmental rigour, editorial independence, relevance and applicability to general practice.&lt;/p&gt;&#xD;&#xA;&lt;p&gt;&lt;strong&gt;Screening Principles&lt;/strong&gt;&lt;/p&gt;&#xD;&#xA;&lt;p&gt;The World Health Organization (WHO) has produced guidelines for the effectiveness of screening programs. The Taskforce has kept these and the United Kingdom National Health Services' guidelines in mind in the development of recommendations about screening and preventive care.&lt;/p&gt;&lt;/div&gt;" /></Field><Field FieldID="146" OrdBy="450" ID="415" Name="Rating Scheme for the Strength of the Recommendations" Type="text"><FieldValue Value="&lt;div class=&quot;content_para&quot;&gt;&lt;p&gt;&lt;strong&gt;Grades of Recommendations&lt;/strong&gt;&lt;/p&gt;&#xD;&#xA;&lt;table border=&quot;1&quot; cellspacing=&quot;1&quot; cellpadding=&quot;3&quot; summary=&quot;Table: Grades of Recommendations&quot;&gt;&#xD;&#xA;    &lt;thead&gt;&#xD;&#xA;        &lt;tr&gt;&#xD;&#xA;            &lt;th valign=&quot;top&quot;&gt;Grade&lt;/th&gt;&#xD;&#xA;            &lt;th valign=&quot;top&quot;&gt;Explanation&lt;/th&gt;&#xD;&#xA;        &lt;/tr&gt;&#xD;&#xA;    &lt;/thead&gt;&#xD;&#xA;    &lt;tbody&gt;&#xD;&#xA;        &lt;tr&gt;&#xD;&#xA;            &lt;td valign=&quot;top&quot;&gt;A&lt;/td&gt;&#xD;&#xA;            &lt;td valign=&quot;top&quot;&gt;Body of evidence can be trusted to guide practice&lt;/td&gt;&#xD;&#xA;        &lt;/tr&gt;&#xD;&#xA;        &lt;tr&gt;&#xD;&#xA;            &lt;td valign=&quot;top&quot;&gt;B&lt;/td&gt;&#xD;&#xA;            &lt;td valign=&quot;top&quot;&gt;Body of evidence can be trusted to guide practice in most situations&lt;/td&gt;&#xD;&#xA;        &lt;/tr&gt;&#xD;&#xA;        &lt;tr&gt;&#xD;&#xA;            &lt;td valign=&quot;top&quot;&gt;C&lt;/td&gt;&#xD;&#xA;            &lt;td valign=&quot;top&quot;&gt;Body of evidence provides some support for recommendation(s) but care should be taken in its application&lt;/td&gt;&#xD;&#xA;        &lt;/tr&gt;&#xD;&#xA;        &lt;tr&gt;&#xD;&#xA;            &lt;td valign=&quot;top&quot;&gt;D&lt;/td&gt;&#xD;&#xA;            &lt;td valign=&quot;top&quot;&gt;Body of evidence is weak and recommendation must be applied with caution&lt;/td&gt;&#xD;&#xA;        &lt;/tr&gt;&#xD;&#xA;    &lt;/tbody&gt;&#xD;&#xA;&lt;/table&gt;&lt;/div&gt;" /></Field><Field FieldID="148" OrdBy="460" ID="417" Name="Cost Analysis" Type="text"><FieldValue Value="&lt;div class=&quot;content_para&quot;&gt;&lt;p&gt;A formal cost analysis was not performed and published cost analyses were not reviewed.&lt;/p&gt;&lt;/div&gt;" /></Field><Field FieldID="104" OrdBy="465" ID="418" Name="Method of Guideline Validation" Type="picklist-choice"><FieldValue Value="Not stated" /></Field><Field FieldID="130" OrdBy="470" ID="419" Name="Description of Method of Guideline Validation" Type="text"><FieldValue Value="&lt;div class=&quot;content_para&quot;&gt;&lt;p&gt;Not applicable&lt;/p&gt;&lt;/div&gt;" /></Field></Section><Section SecID="420" OrdBy="500" Name="Recommendations"><Field FieldID="151" OrdBy="505" ID="421" Name="Major Recommendations" Type="text"><FieldValue Value="&lt;div class=&quot;content_para&quot;&gt;&lt;p&gt;The levels of evidence (&lt;strong&gt;I-IV, Practice Point&lt;/strong&gt;) and grades of recommendations (&lt;strong&gt;A-D&lt;/strong&gt;) are defined at the end of the &quot;Major Recommendations&quot; field.&lt;/p&gt;&#xD;&#xA;&lt;p&gt;&lt;strong&gt;&lt;span style=&quot;text-decoration: underline;&quot;&gt;Assessment of Absolute Cardiovascular Risk&lt;/span&gt;&lt;/strong&gt;&lt;/p&gt;&#xD;&#xA;&lt;p&gt;Absolute cardiovascular risk assessment should be conducted at least every 2 years in all adults aged 45 years and older who are not known to have cardiovascular diseases (CVDs) or to be at clinically determined high risk (National Vascular Disease Prevention Alliance, 2012) (&lt;strong&gt;B&lt;/strong&gt;). This calculation requires information on the patient's age, sex, smoking status, total and high density lipoprotein (HDL) cholesterol, systolic blood pressure (SBP) and if the patient is known to have diabetes or left ventricular hypertrophy (LVH).&lt;/p&gt;&#xD;&#xA;&lt;p&gt;&lt;strong&gt;Cardiovascular Disease: Identifying Risk&lt;/strong&gt;&lt;/p&gt;&#xD;&#xA;&lt;table border=&quot;1&quot; cellspacing=&quot;1&quot; cellpadding=&quot;3&quot; summary=&quot;Table: Cardiovascular Disease: Identifying Risk&quot;&gt;&#xD;&#xA;    &lt;thead&gt;&#xD;&#xA;        &lt;tr&gt;&#xD;&#xA;            &lt;th valign=&quot;top&quot;&gt;Population Group&lt;/th&gt;&#xD;&#xA;            &lt;th valign=&quot;top&quot;&gt;What Should Be Done?&lt;/th&gt;&#xD;&#xA;            &lt;th valign=&quot;top&quot;&gt;How Often?&lt;/th&gt;&#xD;&#xA;            &lt;th valign=&quot;top&quot;&gt;Reference&lt;/th&gt;&#xD;&#xA;        &lt;/tr&gt;&#xD;&#xA;    &lt;/thead&gt;&#xD;&#xA;    &lt;tbody&gt;&#xD;&#xA;        &lt;tr&gt;&#xD;&#xA;            &lt;td valign=&quot;top&quot;&gt;Adults aged 45 years and older not known to have cardiovascular disease (CVD) or not clinically determined to be at high risk.&lt;/td&gt;&#xD;&#xA;            &lt;td valign=&quot;top&quot;&gt;Calculate absolute cardiovascular risk* 45&amp;ndash;74 years. (&lt;strong&gt;II,B&lt;/strong&gt;) &lt;br /&gt;&#xD;&#xA;            &lt;br /&gt;&#xD;&#xA;            &amp;ge;75 years. (&lt;strong&gt;Practice Point&lt;/strong&gt;)&lt;/td&gt;&#xD;&#xA;            &lt;td valign=&quot;top&quot;&gt;Every 2 years&amp;dagger; (&lt;strong&gt;IV,C&lt;/strong&gt;)&lt;/td&gt;&#xD;&#xA;            &lt;td valign=&quot;top&quot;&gt;National Vascular Disease Prevention Alliance, 2012&lt;/td&gt;&#xD;&#xA;        &lt;/tr&gt;&#xD;&#xA;        &lt;tr&gt;&#xD;&#xA;            &lt;td valign=&quot;top&quot;&gt;Aboriginal and Torres Strait Islander peoples aged 35 years and older not known to have CVD or not clinically determined to be at high risk.&lt;/td&gt;&#xD;&#xA;            &lt;td valign=&quot;top&quot;&gt;Assess absolute CVD risk (may underestimate risk). (&lt;strong&gt;IV,C&lt;/strong&gt;)&lt;/td&gt;&#xD;&#xA;            &lt;td valign=&quot;top&quot;&gt;Every 2 years (&lt;strong&gt;IV,C&lt;/strong&gt;)&lt;/td&gt;&#xD;&#xA;            &lt;td valign=&quot;top&quot;&gt;&amp;nbsp;&lt;/td&gt;&#xD;&#xA;        &lt;/tr&gt;&#xD;&#xA;    &lt;/tbody&gt;&#xD;&#xA;&lt;/table&gt;&#xD;&#xA;&lt;p class=&quot;Note&quot;&gt;*Calculate risk using the &lt;em&gt;National Vascular Prevention Disease Alliance charts&lt;/em&gt; (see Appendix 5 in the original guideline document) or online at &lt;a href=&quot;http://www.cvdcheck.org.au&quot; title=&quot;NVDPA Web site&quot;&gt;www.cvdcheck.org.au&lt;/a&gt;. Blood lipid results within 5 years can be used in the calculation of absolute CVD risk, but blood pressure (BP) should be measured at the time of assessment. On-therapy measures of BP and cholesterol may underestimate absolute risk and thus recently recorded pre-treatment measures may be more appropriate to use if available. An electrocardiograph (ECG) is not required to determine LVH if not previously known.&lt;/p&gt;&#xD;&#xA;&lt;p class=&quot;Note&quot;&gt;&amp;dagger;Adults with any of the following do not require absolute CVD risk assessment using the Framingham Risk Equation because they are already known to be at clinically determined high risk of CVD (&lt;strong&gt;IV,D&lt;/strong&gt;):&lt;/p&gt;&#xD;&#xA;&lt;ul class=&quot;contentListFont&quot;&gt;&#xD;&#xA;    &lt;li&gt;Diabetes and age &amp;gt;60 years &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Diabetes with microalbuminuria (&amp;gt;20 &amp;mu;g/min or urine albumin:creatinine ratio [UACR] &amp;gt;2.5 mg/mmol for males, &amp;gt;3.5 mg/mmol for females) &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Moderate or severe chronic kidney disease (CKD) (persistent proteinuria or estimated glomerular filtration rate [eGFR] &amp;lt;45 mL/min/1.73 m&lt;sup&gt;2&lt;/sup&gt;) &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Previous diagnosis of familial hypercholesterolaemia (FH) &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;SBP &amp;ge;180 mmHg or diastolic blood pressure (DBP) &amp;ge;110 mmHg &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Serum total cholesterol &amp;gt;7.5 mmol/L &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Aboriginal or Torres Strait Islander peoples aged over 74 years (&lt;strong&gt;Practice Point&lt;/strong&gt;) &lt;/li&gt;&#xD;&#xA;&lt;/ul&gt;&#xD;&#xA;&lt;p&gt;Adults aged older than 74 years may have their absolute risk assessed with age entered as 74 years. This is likely to underestimate 5-year risk but will give an estimate of minimum risk (National Vascular Disease Prevention Alliance, 2009). Patients with a strong family history of CVD (first-degree relatives) or obesity (body mass index [BMI] above 30 kg/m&lt;sup&gt;2&lt;/sup&gt; or more) may be at greater risk (Welborn, Dhaliwal, &amp;amp; Bennett, 2003; van Dis et al., 2009; Levy et al., 2006). Similarly patients with depression and atrial fibrillation (AF) may be at increased risk (National Vascular Disease Prevention Alliance, 2012).&lt;/p&gt;&#xD;&#xA;&lt;p&gt;See Appendix 5 in the original guideline document or &lt;a href=&quot;http://www.cvdcheck.org.au&quot; title=&quot;NVDPA Web site&quot;&gt;www.cvdcheck.org.au&lt;/a&gt;.&lt;/p&gt;&#xD;&#xA;&lt;p&gt;&lt;strong&gt;&lt;span style=&quot;text-decoration: underline;&quot;&gt;BP&lt;/span&gt;&lt;/strong&gt;&lt;/p&gt;&#xD;&#xA;&lt;p&gt;BP should be measured in all adults from age 18 years (&lt;strong&gt;A&lt;/strong&gt;) at least every 2 years. BP should be interpreted in the context of an absolute cardiovascular risk assessment after age 45 years (35 years of age for Aboriginal and Torres Strait Islander peoples) (&lt;strong&gt;B&lt;/strong&gt;). Secondary causes of hypertension and 'white coat' hypertension should be considered.&lt;/p&gt;&#xD;&#xA;&lt;p&gt;&lt;strong&gt;Hypertension: Identifying Risk&lt;/strong&gt;&lt;/p&gt;&#xD;&#xA;&lt;table border=&quot;1&quot; cellspacing=&quot;1&quot; cellpadding=&quot;3&quot; summary=&quot;Table: Hypertension: Identifying Risk&quot;&gt;&#xD;&#xA;    &lt;thead&gt;&#xD;&#xA;        &lt;tr&gt;&#xD;&#xA;            &lt;th valign=&quot;top&quot;&gt;Who Is at Risk?&lt;/th&gt;&#xD;&#xA;            &lt;th valign=&quot;top&quot;&gt;What Should Be Done?&lt;/th&gt;&#xD;&#xA;            &lt;th valign=&quot;top&quot;&gt;How Often?&lt;/th&gt;&#xD;&#xA;            &lt;th valign=&quot;top&quot;&gt;References&lt;/th&gt;&#xD;&#xA;        &lt;/tr&gt;&#xD;&#xA;    &lt;/thead&gt;&#xD;&#xA;    &lt;tbody&gt;&#xD;&#xA;        &lt;tr&gt;&#xD;&#xA;            &lt;td valign=&quot;top&quot;&gt;&lt;strong&gt;Low Absolute Risk&lt;/strong&gt;&#xD;&#xA;            &lt;ul style=&quot;list-style-type: disc;&quot;&gt;&#xD;&#xA;                &lt;li&gt;&amp;lt;10% cardiovascular disease (CVD) risk &lt;/li&gt;&#xD;&#xA;            &lt;/ul&gt;&#xD;&#xA;            &lt;/td&gt;&#xD;&#xA;            &lt;td valign=&quot;top&quot;&gt;Provide lifestyle advice and education. (&lt;strong&gt;I,B&lt;/strong&gt;)&lt;br /&gt;&#xD;&#xA;            &lt;br /&gt;&#xD;&#xA;            Offer pharmacotherapy if blood pressure (BP) persistently over 160/100 mmHg.&lt;/td&gt;&#xD;&#xA;            &lt;td valign=&quot;top&quot;&gt;BP every 2 years (&lt;strong&gt;III,C&lt;/strong&gt;)&lt;/td&gt;&#xD;&#xA;            &lt;td valign=&quot;top&quot;&gt;National Vascular Disease Prevention Alliance, 2012; U.S. Preventive Services Task Force (USPSTF), 2007; National Heart Foundation of Australia, 2010; Vasan et al., 2001&lt;/td&gt;&#xD;&#xA;        &lt;/tr&gt;&#xD;&#xA;        &lt;tr&gt;&#xD;&#xA;            &lt;td valign=&quot;top&quot;&gt;&lt;strong&gt;Moderate Risk&lt;/strong&gt;&#xD;&#xA;            &lt;ul style=&quot;list-style-type: disc;&quot;&gt;&#xD;&#xA;                &lt;li&gt;10%&amp;ndash;15% absolute cardiovascular risk &lt;/li&gt;&#xD;&#xA;            &lt;/ul&gt;&#xD;&#xA;            &lt;/td&gt;&#xD;&#xA;            &lt;td valign=&quot;top&quot;&gt;Provide intensive lifestyle advice. (&lt;strong&gt;II,B&lt;/strong&gt;)&lt;br /&gt;&#xD;&#xA;            &lt;br /&gt;&#xD;&#xA;            Consider pharmacotherapy if risk factors have not reduced after 3&amp;ndash;6 months of lifestyle intervention.&lt;br /&gt;&#xD;&#xA;            &lt;br /&gt;&#xD;&#xA;            Offer pharmacotherapy simultaneously with lifestyle intervention if BP persistently over 160/100 mmHg or if family history of premature CVD or South Asian, Middle Eastern, Maori, Aboriginal or Pacific Islander descent. (&lt;strong&gt;III,C&lt;/strong&gt;)&lt;/td&gt;&#xD;&#xA;            &lt;td valign=&quot;top&quot;&gt;BP every 6&amp;ndash;12 months (&lt;strong&gt;III,C&lt;/strong&gt;)&lt;/td&gt;&#xD;&#xA;            &lt;td valign=&quot;top&quot;&gt;Welborn, Dhaliwal, &amp;amp; Bennett, 2003; National Vascular Disease Prevention Alliance, 2012; van Dis et al., 2009; Levy et al., 2006; USPSTF, 2007; Australian Institute of Health and Welfare, 2001&lt;/td&gt;&#xD;&#xA;        &lt;/tr&gt;&#xD;&#xA;        &lt;tr&gt;&#xD;&#xA;            &lt;td valign=&quot;top&quot; rowspan=&quot;3&quot;&gt;&lt;strong&gt;High Risk&lt;/strong&gt;&#xD;&#xA;            &lt;ul style=&quot;list-style-type: disc;&quot;&gt;&#xD;&#xA;                &lt;li&gt;&amp;gt;15% absolute cardiovascular risk &lt;/li&gt;&#xD;&#xA;                &lt;li&gt;Clinically determined high risk:&#xD;&#xA;                &lt;ul style=&quot;list-style-type: disc;&quot;&gt;&#xD;&#xA;                    &lt;li&gt;Diabetes and age &amp;gt;60 years &lt;/li&gt;&#xD;&#xA;                    &lt;li&gt;Diabetes with microalbuminuria (&amp;gt;20 &amp;mu;g/min or urine albumin-to-creatinine ratio [UACR] &amp;gt;2.5 mg/mmol for males, &amp;gt;3.5 mg/mmol for females) &lt;/li&gt;&#xD;&#xA;                    &lt;li&gt;Moderate or severe chronic kidney disease (CKD) (persistent proteinuria or estimated glomerular filtration rate (eGFR) &amp;lt;45 mL/min/1.73 m&lt;sup&gt;2&lt;/sup&gt;) &lt;/li&gt;&#xD;&#xA;                    &lt;li&gt;Previous diagnosis of familial hypercholesterolaemia (FH) &lt;/li&gt;&#xD;&#xA;                    &lt;li&gt;Systolic blood pressure (SBP) &amp;ge;180 mmHg or diastolic blood pressure (DBP) &amp;ge;110 mmHg &lt;/li&gt;&#xD;&#xA;                    &lt;li&gt;Serum total cholesterol &amp;gt;7.5 mmol/L &lt;/li&gt;&#xD;&#xA;                    &lt;li&gt;Aboriginal and Torres Strait Islander peoples aged over 74 years &lt;/li&gt;&#xD;&#xA;                &lt;/ul&gt;&#xD;&#xA;                &lt;/li&gt;&#xD;&#xA;            &lt;/ul&gt;&#xD;&#xA;            &lt;/td&gt;&#xD;&#xA;            &lt;td valign=&quot;top&quot;&gt;Provide intensive lifestyle advice (&lt;strong&gt;II,B&lt;/strong&gt;)&lt;/td&gt;&#xD;&#xA;            &lt;td valign=&quot;top&quot; rowspan=&quot;3&quot;&gt;BP every 6&amp;ndash;12 weeks (&lt;strong&gt;III,C&lt;/strong&gt;)&lt;/td&gt;&#xD;&#xA;            &lt;td valign=&quot;top&quot;&gt;National Vascular Disease Prevention Alliance, 2012; National Heart Foundation of Australia, 2010&lt;/td&gt;&#xD;&#xA;        &lt;/tr&gt;&#xD;&#xA;        &lt;tr&gt;&#xD;&#xA;            &lt;td valign=&quot;top&quot;&gt;Commence pharmacotherapy (simultaneously with lipid therapy unless contraindicated).&lt;/td&gt;&#xD;&#xA;            &lt;td valign=&quot;top&quot;&gt;&amp;nbsp;&lt;/td&gt;&#xD;&#xA;        &lt;/tr&gt;&#xD;&#xA;        &lt;tr&gt;&#xD;&#xA;            &lt;td valign=&quot;top&quot;&gt;Treatment goal is BP &amp;lt;140/90 mmHg in adults without CVD including those with CKD (&lt;strong&gt;I,B&amp;ndash;III,D&lt;/strong&gt;)* (&amp;le;130/80 in people with diabetes or micro or macroalbuminuria [UACR &amp;gt;2.5 mg/mmol in males and &amp;gt;3.5 mg/mmol in females]).&lt;/td&gt;&#xD;&#xA;            &lt;td valign=&quot;top&quot;&gt;Go et al., 2004; Culleton et al., 1999&lt;/td&gt;&#xD;&#xA;        &lt;/tr&gt;&#xD;&#xA;        &lt;tr&gt;&#xD;&#xA;            &lt;td valign=&quot;top&quot;&gt;&lt;strong&gt;High Risk&lt;/strong&gt;&lt;br /&gt;&#xD;&#xA;            &lt;br /&gt;&#xD;&#xA;            Existing CVD (previous event, symptomatic CVD), stroke or transient ischaemic attacks (TIA) or CKD&lt;/td&gt;&#xD;&#xA;            &lt;td valign=&quot;top&quot;&gt;Lifestyle risk factor counseling&lt;br /&gt;&#xD;&#xA;            &lt;br /&gt;&#xD;&#xA;            Pharmacotherapy to lower risk (&lt;strong&gt;I,A&lt;/strong&gt;)&lt;/td&gt;&#xD;&#xA;            &lt;td valign=&quot;top&quot;&gt;Every 6 months (&lt;strong&gt;III,C&lt;/strong&gt;)&lt;/td&gt;&#xD;&#xA;            &lt;td valign=&quot;top&quot;&gt;National Heart Foundation of Australia, 2010&lt;/td&gt;&#xD;&#xA;        &lt;/tr&gt;&#xD;&#xA;    &lt;/tbody&gt;&#xD;&#xA;&lt;/table&gt;&#xD;&#xA;&lt;p class=&quot;Note&quot;&gt;*D recommendation for clinically determined high risk.&lt;/p&gt;&#xD;&#xA;&lt;p&gt;&lt;strong&gt;Hypertension: Preventive Interventions&lt;/strong&gt;&lt;/p&gt;&#xD;&#xA;&lt;table border=&quot;1&quot; cellspacing=&quot;1&quot; cellpadding=&quot;3&quot; summary=&quot;Table: Hypertension: Preventive Interventions&quot;&gt;&#xD;&#xA;    &lt;thead&gt;&#xD;&#xA;        &lt;tr&gt;&#xD;&#xA;            &lt;th valign=&quot;top&quot;&gt;&lt;strong&gt;Intervention&lt;/strong&gt;&lt;/th&gt;&#xD;&#xA;            &lt;th valign=&quot;top&quot;&gt;Technique&lt;/th&gt;&#xD;&#xA;            &lt;th valign=&quot;top&quot;&gt;References&lt;/th&gt;&#xD;&#xA;        &lt;/tr&gt;&#xD;&#xA;    &lt;/thead&gt;&#xD;&#xA;    &lt;tbody&gt;&#xD;&#xA;        &lt;tr&gt;&#xD;&#xA;            &lt;td valign=&quot;top&quot;&gt;Measure blood pressure (BP)&lt;/td&gt;&#xD;&#xA;            &lt;td valign=&quot;top&quot;&gt;Measure BP on at least 2 separate occasions with a calibrated mercury sphygmomanometer, or automated device that is regularly calibrated against a mercury sphygmomanometer. At the patient's first BP assessment, measure BP on both arms. Thereafter, use the arm with the higher reading. In patients who may have orthostatic hypotension (e.g., the elderly, those with diabetes), measure BP in sitting position and repeat after the patient has been standing for at least 2 minutes. &lt;br /&gt;&#xD;&#xA;            &lt;br /&gt;&#xD;&#xA;            If possible, use ambulatory BP monitoring or self-measurement for patients with any of the following:&#xD;&#xA;            &lt;ul style=&quot;list-style-type: disc;&quot;&gt;&#xD;&#xA;                &lt;li&gt;Unusual variation between BP readings in the clinic &lt;/li&gt;&#xD;&#xA;                &lt;li&gt;Suspected 'white coat' hypertension &lt;/li&gt;&#xD;&#xA;                &lt;li&gt;Hypertension that is resistant to drug treatment &lt;/li&gt;&#xD;&#xA;                &lt;li&gt;Suspected hypotensive episodes (e.g., in elderly or diabetic patients) &lt;/li&gt;&#xD;&#xA;            &lt;/ul&gt;&#xD;&#xA;            Risk calculation should be performed using clinical BP measurements (as the algorithms are based on these). Ambulatory BP readings are considered to be better predictors of outcomes than clinic BP measurements, and therefore should be used to monitor BP lowering therapy.&lt;/td&gt;&#xD;&#xA;            &lt;td valign=&quot;top&quot;&gt;National Vascular Disease Prevention Alliance, 2012; National Heart Foundation of Australia, 2010&lt;/td&gt;&#xD;&#xA;        &lt;/tr&gt;&#xD;&#xA;        &lt;tr&gt;&#xD;&#xA;            &lt;td valign=&quot;top&quot;&gt;Lifestyle modification&lt;/td&gt;&#xD;&#xA;            &lt;td valign=&quot;top&quot;&gt;Lifestyle risk factors should be managed at all risk levels. &lt;br /&gt;&#xD;&#xA;            &lt;br /&gt;&#xD;&#xA;            All people, regardless of their absolute risk level, should be given dietary advice. Those at low to moderate absolute risk of cardiovascular disease (CVD) should be given dietary and other lifestyle advice (See the NGC summary of the Royal Australian College of General Practitioners [RACGP] guideline &lt;a href=&quot;/content.aspx?id=43853&quot; title=&quot;Guideline #9645&quot;&gt;Prevention of chronic disease&lt;/a&gt;.)&lt;br /&gt;&#xD;&#xA;            &lt;br /&gt;&#xD;&#xA;            Advise to aim for healthy targets:&#xD;&#xA;            &lt;ul style=&quot;list-style-type: disc;&quot;&gt;&#xD;&#xA;                &lt;li&gt;At least 30 minutes of moderate-intensity physical activity on most, if not all, days &lt;/li&gt;&#xD;&#xA;                &lt;li&gt;Smoking cessation &lt;/li&gt;&#xD;&#xA;                &lt;li&gt;Waist measurement &amp;lt;94 cm for men and &amp;lt;80 cm for women, body mass index (BMI) &amp;lt;25 kg/m&lt;sup&gt;2&lt;/sup&gt; &lt;/li&gt;&#xD;&#xA;                &lt;li&gt;Dietary salt restriction &amp;le;4 g/day (65 mmol/day sodium) &lt;/li&gt;&#xD;&#xA;                &lt;li&gt;Limit alcohol intake to &amp;le;2 standard drinks per day for males and &amp;le;1 standard drink per day for females &lt;/li&gt;&#xD;&#xA;            &lt;/ul&gt;&#xD;&#xA;            &lt;/td&gt;&#xD;&#xA;            &lt;td valign=&quot;top&quot;&gt;National Vascular Disease Prevention Alliance, 2012; National Heart Foundation of Australia, 2010&lt;/td&gt;&#xD;&#xA;        &lt;/tr&gt;&#xD;&#xA;        &lt;tr&gt;&#xD;&#xA;            &lt;td valign=&quot;top&quot;&gt;Medications&lt;/td&gt;&#xD;&#xA;            &lt;td valign=&quot;top&quot;&gt;BP treatment should aim to lower BP towards (while balancing risks and benefits):&#xD;&#xA;            &lt;ul style=&quot;list-style-type: disc;&quot;&gt;&#xD;&#xA;                &lt;li&gt;&amp;le;140/90 for adults without CVD (including those with chronic kidney disease [CKD]) &lt;/li&gt;&#xD;&#xA;                &lt;li&gt;&amp;le;130/80 for adults with diabetes or with micro- or macro-albuminuria (urine albumin-to-creatinine ratio [UACR] &amp;gt;2.5 mg/mmol for males, &amp;gt;3.5 mg/mmol for females) &lt;/li&gt;&#xD;&#xA;            &lt;/ul&gt;&#xD;&#xA;            Treatment may commence with an angiotensin converting enzyme (ACE) inhibitor, angiotensin II antagonist, calcium channel blocker or a low-dose thiazide or thiazide-like diuretic. A second or third agent from a different class may be added to treat towards targets.&lt;/td&gt;&#xD;&#xA;            &lt;td valign=&quot;top&quot;&gt;National Vascular Disease Prevention Alliance, 2012&lt;/td&gt;&#xD;&#xA;        &lt;/tr&gt;&#xD;&#xA;    &lt;/tbody&gt;&#xD;&#xA;&lt;/table&gt;&#xD;&#xA;&lt;p&gt;&lt;strong&gt;&lt;span style=&quot;text-decoration: underline;&quot;&gt;Cholesterol and Other Lipids&lt;/span&gt;&lt;/strong&gt;&lt;/p&gt;&#xD;&#xA;&lt;p&gt;Adults should have their fasting blood lipids assessed starting at age 45 years, every 5 years (&lt;strong&gt;A&lt;/strong&gt; for males, &lt;strong&gt;C&lt;/strong&gt; for females). Lipid levels should be interpreted in the context of an absolute cardiovascular risk assessment after age 45 years (35 years for Aboriginal and Torres Strait Islander peoples) (&lt;strong&gt;B&lt;/strong&gt;). Aboriginal and Torres Strait Islander adults should have fasting lipid tests performed every 5 years from age 35 years (&lt;strong&gt;B&lt;/strong&gt;).&lt;/p&gt;&#xD;&#xA;&lt;p&gt;&lt;strong&gt;Cholesterol and Lipids: Identifying Risk&lt;/strong&gt;&lt;/p&gt;&#xD;&#xA;&lt;table border=&quot;1&quot; cellspacing=&quot;1&quot; cellpadding=&quot;3&quot; summary=&quot;Table: Cholesterol and Lipids: Identifying Risk&quot;&gt;&#xD;&#xA;    &lt;thead&gt;&#xD;&#xA;        &lt;tr&gt;&#xD;&#xA;            &lt;th valign=&quot;top&quot;&gt;Who Is at Risk?&lt;/th&gt;&#xD;&#xA;            &lt;th valign=&quot;top&quot;&gt;What Should Be Done?&lt;/th&gt;&#xD;&#xA;            &lt;th valign=&quot;top&quot;&gt;How Often?&lt;/th&gt;&#xD;&#xA;            &lt;th valign=&quot;top&quot;&gt;References&lt;/th&gt;&#xD;&#xA;        &lt;/tr&gt;&#xD;&#xA;    &lt;/thead&gt;&#xD;&#xA;    &lt;tbody&gt;&#xD;&#xA;        &lt;tr&gt;&#xD;&#xA;            &lt;td valign=&quot;top&quot;&gt;&lt;strong&gt;Low Risk&lt;/strong&gt;&#xD;&#xA;            &lt;ul style=&quot;list-style-type: disc;&quot;&gt;&#xD;&#xA;                &lt;li&gt;Absolute cardiovascular disease (CVD) risk &amp;lt;10% &lt;/li&gt;&#xD;&#xA;            &lt;/ul&gt;&#xD;&#xA;            &lt;/td&gt;&#xD;&#xA;            &lt;td valign=&quot;top&quot;&gt;Provide lifestyle advice. (&lt;strong&gt;I,A&lt;/strong&gt;)&lt;/td&gt;&#xD;&#xA;            &lt;td valign=&quot;top&quot;&gt;Repeat fasting lipids every 5 years*&lt;/td&gt;&#xD;&#xA;            &lt;td valign=&quot;top&quot;&gt;National Vascular Disease Prevention Alliance, 2012&lt;/td&gt;&#xD;&#xA;        &lt;/tr&gt;&#xD;&#xA;        &lt;tr&gt;&#xD;&#xA;            &lt;td valign=&quot;top&quot;&gt;&lt;strong&gt;Moderate Risk&lt;/strong&gt;&#xD;&#xA;            &lt;ul style=&quot;list-style-type: disc;&quot;&gt;&#xD;&#xA;                &lt;li&gt;Absolute CVD risk 10%&amp;ndash;15% &lt;/li&gt;&#xD;&#xA;            &lt;/ul&gt;&#xD;&#xA;            &lt;/td&gt;&#xD;&#xA;            &lt;td valign=&quot;top&quot;&gt;Provide intensive lifestyle advice. (&lt;strong&gt;II,B&lt;/strong&gt;) &lt;br /&gt;&#xD;&#xA;            &lt;br /&gt;&#xD;&#xA;            Consider pharmacotherapy if not reaching target after 6 months (&lt;strong&gt;I,A&lt;/strong&gt;) or if family history of premature CVD, or Aboriginal or Torres Strait Islander, South Asian, Middle Eastern, Maori or Pacific Islander descent. (&lt;strong&gt;II,C&lt;/strong&gt;)&lt;/td&gt;&#xD;&#xA;            &lt;td valign=&quot;top&quot;&gt;Repeat fasting lipids every 2 years&lt;/td&gt;&#xD;&#xA;            &lt;td valign=&quot;top&quot;&gt;Welborn, Dhaliwal, &amp;amp; Bennett, 2003; National Vascular Disease Prevention Alliance, 2012; van Dis et al., 2009; Levy et al., 2006&lt;/td&gt;&#xD;&#xA;        &lt;/tr&gt;&#xD;&#xA;        &lt;tr&gt;&#xD;&#xA;            &lt;td valign=&quot;top&quot;&gt;&lt;strong&gt;High Risk&lt;/strong&gt;&#xD;&#xA;            &lt;ul style=&quot;list-style-type: disc;&quot;&gt;&#xD;&#xA;                &lt;li&gt;Absolute cardiovascular risk &amp;gt;15% &lt;/li&gt;&#xD;&#xA;                &lt;li&gt;Patient with the following clinically determined high-risk factors:&#xD;&#xA;                &lt;ul style=&quot;list-style-type: disc;&quot;&gt;&#xD;&#xA;                    &lt;li&gt;Diabetes and age &amp;gt;60 years &lt;/li&gt;&#xD;&#xA;                    &lt;li&gt;Diabetes with microalbuminuria (&amp;gt;20 &amp;mu;g/min or urine albumin-to-creatinine ratio [UACR] &amp;gt;2.5 mg/mmol for males, &amp;gt;3.5 mg/mmol for females) &lt;/li&gt;&#xD;&#xA;                    &lt;li&gt;Chronic kidney disease (CKD) persistent microalbuminuria or Stage 4 renal failure (estimated glomerular filtration rate [eGFR] &amp;lt;30 mL/min/1.73 m&lt;sup&gt;2&lt;/sup&gt;) or Stage 3a renal failure (eGFR &amp;lt;45 mL/min/1.73 m&lt;sup&gt;2&lt;/sup&gt;) &lt;/li&gt;&#xD;&#xA;                    &lt;li&gt;Previous diagnosis of familial hypercholesterolaemia (FH) &lt;/li&gt;&#xD;&#xA;                    &lt;li&gt;Systolic blood pressure (SBP) &amp;gt;180 mmHg or diastolic blood pressure (DBP) &amp;gt;110 mmHg &lt;/li&gt;&#xD;&#xA;                    &lt;li&gt;Serum total cholesterol &amp;gt;7.5 mmol/L &lt;/li&gt;&#xD;&#xA;                    &lt;li&gt;Aboriginal and Torres Strait Islander peoples aged over 74 years &lt;/li&gt;&#xD;&#xA;                &lt;/ul&gt;&#xD;&#xA;                &lt;/li&gt;&#xD;&#xA;            &lt;/ul&gt;&#xD;&#xA;            See the &quot;BP&quot; section above.&lt;/td&gt;&#xD;&#xA;            &lt;td valign=&quot;top&quot;&gt;Provide intensive lifestyle advice. (&lt;strong&gt;II,C&lt;/strong&gt;)&lt;br /&gt;&#xD;&#xA;            &lt;br /&gt;&#xD;&#xA;            Commence cholesterol lowering therapy (simultaneously with antihypertensive unless contraindicated).&amp;dagger; (&lt;strong&gt;II,C-III,D&lt;/strong&gt;)&lt;/td&gt;&#xD;&#xA;            &lt;td valign=&quot;top&quot;&gt;Every 12 months (&lt;strong&gt;III,C&lt;/strong&gt;)&lt;/td&gt;&#xD;&#xA;            &lt;td valign=&quot;top&quot;&gt;National Vascular Disease Prevention Alliance, 2012&lt;/td&gt;&#xD;&#xA;        &lt;/tr&gt;&#xD;&#xA;        &lt;tr&gt;&#xD;&#xA;            &lt;td valign=&quot;top&quot;&gt;&lt;strong&gt;High Risk&lt;/strong&gt;&lt;br /&gt;&#xD;&#xA;            &lt;br /&gt;&#xD;&#xA;            Existing CVD (previous event, symptomatic CVD).&lt;/td&gt;&#xD;&#xA;            &lt;td valign=&quot;top&quot;&gt;Lifestyle risk factor counselling&lt;br /&gt;&#xD;&#xA;            &lt;br /&gt;&#xD;&#xA;            Pharmacotherapy to lower risk (&lt;strong&gt;I,A&lt;/strong&gt;)&lt;/td&gt;&#xD;&#xA;            &lt;td valign=&quot;top&quot;&gt;Every 12 months (&lt;strong&gt;III,C&lt;/strong&gt;)&lt;/td&gt;&#xD;&#xA;            &lt;td valign=&quot;top&quot;&gt;National Stroke Foundation (NSF), 2010&lt;/td&gt;&#xD;&#xA;        &lt;/tr&gt;&#xD;&#xA;    &lt;/tbody&gt;&#xD;&#xA;&lt;/table&gt;&#xD;&#xA;&lt;p class=&quot;Note&quot;&gt;*Lipid blood test results within 5 years can be used to calculate absolute CVD risk every 2 years. Patients with diabetes, cardiac disease, stroke, hypertension or kidney disease should have their lipids tested every 12 months (&lt;strong&gt;III,C&lt;/strong&gt;).&lt;/p&gt;&#xD;&#xA;&lt;p class=&quot;Note&quot;&gt;&amp;dagger;D recommendation for clinically determined high risk.&lt;/p&gt;&#xD;&#xA;&lt;p&gt;&lt;strong&gt;Cholesterol and Lipids: Preventive Interventions&lt;/strong&gt;&lt;/p&gt;&#xD;&#xA;&lt;table border=&quot;1&quot; cellspacing=&quot;1&quot; cellpadding=&quot;3&quot; summary=&quot;Table: Cholesterol and Lipids: Preventive Interventions&quot;&gt;&#xD;&#xA;    &lt;thead&gt;&#xD;&#xA;        &lt;tr&gt;&#xD;&#xA;            &lt;th valign=&quot;top&quot;&gt;Intervention&lt;/th&gt;&#xD;&#xA;            &lt;th valign=&quot;top&quot;&gt;Technique&lt;/th&gt;&#xD;&#xA;            &lt;th valign=&quot;top&quot;&gt;References&lt;/th&gt;&#xD;&#xA;        &lt;/tr&gt;&#xD;&#xA;    &lt;/thead&gt;&#xD;&#xA;    &lt;tbody&gt;&#xD;&#xA;        &lt;tr&gt;&#xD;&#xA;            &lt;td valign=&quot;top&quot; rowspan=&quot;3&quot;&gt;Fasting blood lipids&lt;/td&gt;&#xD;&#xA;            &lt;td valign=&quot;top&quot;&gt;Fasting total cholesterol, low-density lipoprotein (LDL) cholesterol, high-density lipoprotein (HDL) cholesterol and triglycerides (TG). If lipid levels are abnormal, a second confirmatory sample should be taken on a separate occasion (as levels may vary between tests) before a definitive diagnosis is made.&lt;/td&gt;&#xD;&#xA;            &lt;td valign=&quot;top&quot;&gt;Tonkin et al., 2005&lt;/td&gt;&#xD;&#xA;        &lt;/tr&gt;&#xD;&#xA;        &lt;tr&gt;&#xD;&#xA;            &lt;td valign=&quot;top&quot;&gt;Screening tests using capillary blood samples produce total cholesterol results that are slightly lower than on venous blood. These may be used, providing they are confirmed with full laboratory testing of venous blood for patients with elevated levels and there is good follow-up.&lt;/td&gt;&#xD;&#xA;            &lt;td valign=&quot;top&quot;&gt;Bachorik et al., 1991; Bradford et al., 1990&lt;/td&gt;&#xD;&#xA;        &lt;/tr&gt;&#xD;&#xA;        &lt;tr&gt;&#xD;&#xA;            &lt;td valign=&quot;top&quot;&gt;In adults at low absolute risk of cardiovascular disease (CVD), blood test results within 5 years may be used for review of absolute cardiovascular risk unless there are reasons to the contrary.&lt;/td&gt;&#xD;&#xA;            &lt;td valign=&quot;top&quot;&gt;&amp;nbsp;&lt;/td&gt;&#xD;&#xA;        &lt;/tr&gt;&#xD;&#xA;        &lt;tr&gt;&#xD;&#xA;            &lt;td valign=&quot;top&quot;&gt;Lifestyle modification&lt;/td&gt;&#xD;&#xA;            &lt;td valign=&quot;top&quot;&gt;Lifestyle risk factors should be managed at all risk levels.&lt;br /&gt;&#xD;&#xA;            &lt;br /&gt;&#xD;&#xA;            All people, regardless of their absolute risk level, should be given dietary advice Those at low to moderate absolute risk of CVD should be given dietary and other lifestyle advice (see the NGC summary of the RACGP guideline &lt;a href=&quot;/content.aspx?id=43853&quot; title=&quot;Guideline #9645&quot;&gt;Prevention of chronic disease&lt;/a&gt;).&lt;br /&gt;&#xD;&#xA;            &lt;br /&gt;&#xD;&#xA;            Advise to aim for healthy targets:&#xD;&#xA;            &lt;ul style=&quot;list-style-type: disc;&quot;&gt;&#xD;&#xA;                &lt;li&gt;At least 30 minutes of moderate-intensity physical activity on most, if not all, days &lt;/li&gt;&#xD;&#xA;                &lt;li&gt;Smoking cessation &lt;/li&gt;&#xD;&#xA;                &lt;li&gt;Waist measurement &amp;lt;94 cm for men and &amp;lt;80 cm for women, body mass index (BMI) &amp;lt;25 kg/m&lt;sup&gt;2&lt;/sup&gt; &lt;/li&gt;&#xD;&#xA;                &lt;li&gt;Dietary salt restriction &amp;le;4 g/day (65 mmol/day sodium) &lt;/li&gt;&#xD;&#xA;                &lt;li&gt;Limit alcohol intake to &amp;le;2 standard drinks per day for men and &amp;le;1 standard drink per day for women &lt;/li&gt;&#xD;&#xA;            &lt;/ul&gt;&#xD;&#xA;            &lt;/td&gt;&#xD;&#xA;            &lt;td valign=&quot;top&quot;&gt;National Vascular Disease Prevention Alliance, 2012; National Heart Foundation of Australia, 2010&lt;/td&gt;&#xD;&#xA;        &lt;/tr&gt;&#xD;&#xA;        &lt;tr&gt;&#xD;&#xA;            &lt;td valign=&quot;top&quot;&gt;Pharmacotherapy&lt;/td&gt;&#xD;&#xA;            &lt;td valign=&quot;top&quot;&gt;Lipid lowering therapy for primary prevention should (while balancing risks and benefits) aim towards:&#xD;&#xA;            &lt;ul style=&quot;list-style-type: disc;&quot;&gt;&#xD;&#xA;                &lt;li&gt;Total cholesterol &amp;lt;4.0 mmol/L &lt;/li&gt;&#xD;&#xA;                &lt;li&gt;HDL-C &amp;ge;1.0 mmol/L &lt;/li&gt;&#xD;&#xA;                &lt;li&gt;LDL-C &amp;lt;2.0 mmol/L &lt;/li&gt;&#xD;&#xA;                &lt;li&gt;Non-HDL-C &amp;lt;2.5 mmol/L &lt;/li&gt;&#xD;&#xA;                &lt;li&gt;TG &amp;lt;2.0 mmol/L &lt;/li&gt;&#xD;&#xA;            &lt;/ul&gt;&#xD;&#xA;            Treatment should commence with a statin. If LDL-C levels are not sufficiently reduced on maximally tolerated dose of a statin, add one of ezetimibe, bile acid binding resin or nicotinic acid. These agents may be used as monotherapy if statins cannot be tolerated at all. If TG levels remain elevated, consider use of one of fenofibrate, nicotinic acid or fish oil.&lt;/td&gt;&#xD;&#xA;            &lt;td valign=&quot;top&quot;&gt;National Vascular Disease Prevention Alliance, 2012&lt;/td&gt;&#xD;&#xA;        &lt;/tr&gt;&#xD;&#xA;    &lt;/tbody&gt;&#xD;&#xA;&lt;/table&gt;&#xD;&#xA;&lt;p&gt;&lt;strong&gt;&lt;span style=&quot;text-decoration: underline;&quot;&gt;Type 2 Diabetes&lt;/span&gt;&lt;/strong&gt;&lt;/p&gt;&#xD;&#xA;&lt;p&gt;Patients should be screened for diabetes every 3 years from age 40 years using the Australian Type 2 Diabetes Risk Assessment Tool (AUSDRISK) (&lt;strong&gt;B&lt;/strong&gt;). Aboriginal and Torres Strait Islander peoples should be screened from age 18 years. Those with a risk score of 12 or more should be tested by fasting plasma glucose (&lt;strong&gt;C&lt;/strong&gt;).&lt;/p&gt;&#xD;&#xA;&lt;p&gt;&lt;strong&gt;Type 2 Diabetes: Identifying Risk&lt;/strong&gt;&lt;/p&gt;&#xD;&#xA;&lt;table border=&quot;1&quot; cellspacing=&quot;1&quot; cellpadding=&quot;3&quot; summary=&quot;Table: Type 2 Diabetes: Identifying Risk&quot;&gt;&#xD;&#xA;    &lt;thead&gt;&#xD;&#xA;        &lt;tr&gt;&#xD;&#xA;            &lt;th valign=&quot;top&quot;&gt;Who Is at Risk?&lt;/th&gt;&#xD;&#xA;            &lt;th valign=&quot;top&quot;&gt;What Should Be Done?&lt;/th&gt;&#xD;&#xA;            &lt;th valign=&quot;top&quot;&gt;How Often?&lt;/th&gt;&#xD;&#xA;            &lt;th valign=&quot;top&quot;&gt;References&lt;/th&gt;&#xD;&#xA;        &lt;/tr&gt;&#xD;&#xA;    &lt;/thead&gt;&#xD;&#xA;    &lt;tbody&gt;&#xD;&#xA;        &lt;tr&gt;&#xD;&#xA;            &lt;td valign=&quot;top&quot;&gt;&lt;strong&gt;Increased Risk&lt;/strong&gt;&#xD;&#xA;            &lt;ul style=&quot;list-style-type: disc;&quot;&gt;&#xD;&#xA;                &lt;li&gt;Age &amp;gt;40 years &lt;/li&gt;&#xD;&#xA;                &lt;li&gt;Aboriginal and Torres Strait Islander peoples &lt;/li&gt;&#xD;&#xA;            &lt;/ul&gt;&#xD;&#xA;            &lt;/td&gt;&#xD;&#xA;            &lt;td valign=&quot;top&quot;&gt;Australian Type 2 Diabetes Risk Assessment Tool (AUSDRISK) (&lt;strong&gt;III,B&lt;/strong&gt;) (See Appendix 4 in the original guideline document).&lt;/td&gt;&#xD;&#xA;            &lt;td valign=&quot;top&quot;&gt;Every 3 years (&lt;strong&gt;III,C&lt;/strong&gt;)&lt;/td&gt;&#xD;&#xA;            &lt;td valign=&quot;top&quot;&gt;National Health and Medical Research Council (NHMRC), 2009&lt;/td&gt;&#xD;&#xA;        &lt;/tr&gt;&#xD;&#xA;        &lt;tr&gt;&#xD;&#xA;            &lt;td valign=&quot;top&quot;&gt;&lt;strong&gt;High Risk&lt;/strong&gt;&#xD;&#xA;            &lt;ul style=&quot;list-style-type: disc;&quot;&gt;&#xD;&#xA;                &lt;li&gt;Any 1 of following risk factors:&#xD;&#xA;                &lt;ul style=&quot;list-style-type: disc;&quot;&gt;&#xD;&#xA;                    &lt;li&gt;AUSDRISK score of 12 or more &lt;/li&gt;&#xD;&#xA;                    &lt;li&gt;All people with a history of a previous cardiovascular event (acute myocardial infarction or stroke) &lt;/li&gt;&#xD;&#xA;                    &lt;li&gt;Women with a history of gestational diabetes mellitus &lt;/li&gt;&#xD;&#xA;                    &lt;li&gt;Women with polycystic ovary syndrome &lt;/li&gt;&#xD;&#xA;                    &lt;li&gt;Patients on antipsychotic drugs &lt;/li&gt;&#xD;&#xA;                &lt;/ul&gt;&#xD;&#xA;                &lt;/li&gt;&#xD;&#xA;            &lt;/ul&gt;&#xD;&#xA;            &lt;/td&gt;&#xD;&#xA;            &lt;td valign=&quot;top&quot;&gt;Fasting blood sugar (&lt;strong&gt;III,B&lt;/strong&gt;)&lt;/td&gt;&#xD;&#xA;            &lt;td valign=&quot;top&quot;&gt;Every 3 years (&lt;strong&gt;III,C&lt;/strong&gt;)&lt;/td&gt;&#xD;&#xA;            &lt;td valign=&quot;top&quot;&gt;NHMRC, 2005; Iseki et al., 2003&lt;/td&gt;&#xD;&#xA;        &lt;/tr&gt;&#xD;&#xA;        &lt;tr&gt;&#xD;&#xA;            &lt;td valign=&quot;top&quot;&gt;&lt;strong&gt;High Risk&lt;/strong&gt;&#xD;&#xA;            &lt;ul style=&quot;list-style-type: disc;&quot;&gt;&#xD;&#xA;                &lt;li&gt;Those with impaired glucose tolerance test or impaired fasting glucose (not limited by age) &lt;/li&gt;&#xD;&#xA;            &lt;/ul&gt;&#xD;&#xA;            &lt;/td&gt;&#xD;&#xA;            &lt;td valign=&quot;top&quot;&gt;Fasting blood sugar (&lt;strong&gt;III,B&lt;/strong&gt;)&lt;/td&gt;&#xD;&#xA;            &lt;td valign=&quot;top&quot;&gt;Every 12 months (&lt;strong&gt;III,C&lt;/strong&gt;)&lt;/td&gt;&#xD;&#xA;            &lt;td valign=&quot;top&quot;&gt;NHMRC, 2005&lt;/td&gt;&#xD;&#xA;        &lt;/tr&gt;&#xD;&#xA;    &lt;/tbody&gt;&#xD;&#xA;&lt;/table&gt;&#xD;&#xA;&lt;p&gt;&lt;strong&gt;Tests to Detect Diabetes&lt;/strong&gt;&lt;/p&gt;&#xD;&#xA;&lt;table border=&quot;1&quot; cellspacing=&quot;1&quot; cellpadding=&quot;3&quot; summary=&quot;Table: Tests to Detect Diabetes&quot;&gt;&#xD;&#xA;    &lt;thead&gt;&#xD;&#xA;        &lt;tr&gt;&#xD;&#xA;            &lt;th valign=&quot;top&quot;&gt;Test&lt;/th&gt;&#xD;&#xA;            &lt;th valign=&quot;top&quot;&gt;Technique&lt;/th&gt;&#xD;&#xA;            &lt;th valign=&quot;top&quot;&gt;References&lt;/th&gt;&#xD;&#xA;        &lt;/tr&gt;&#xD;&#xA;    &lt;/thead&gt;&#xD;&#xA;    &lt;tbody&gt;&#xD;&#xA;        &lt;tr&gt;&#xD;&#xA;            &lt;td valign=&quot;top&quot;&gt;Fasting blood sugar&lt;/td&gt;&#xD;&#xA;            &lt;td valign=&quot;top&quot;&gt;Measure plasma glucose levels on a fasting sample.&#xD;&#xA;            &lt;ul style=&quot;list-style-type: disc;&quot;&gt;&#xD;&#xA;                &lt;li&gt;&amp;lt;5.5 mmol/L: diabetes unlikely &lt;/li&gt;&#xD;&#xA;                &lt;li&gt;5.5&amp;ndash;6.9 mmol/L fasting: may need to perform an oral glucose tolerance test &lt;/li&gt;&#xD;&#xA;                &lt;li&gt;7.0 mmol/L or more fasting (&amp;gt;11.1 non-fasting): diabetes likely, repeat fasting blood sugar to confirm on a separate day &lt;/li&gt;&#xD;&#xA;            &lt;/ul&gt;&#xD;&#xA;            The test should be performed on venous blood and tested in a laboratory to confirm a diagnosis.&lt;/td&gt;&#xD;&#xA;            &lt;td valign=&quot;top&quot;&gt;NHMRC, 2005&lt;/td&gt;&#xD;&#xA;        &lt;/tr&gt;&#xD;&#xA;        &lt;tr&gt;&#xD;&#xA;            &lt;td valign=&quot;top&quot;&gt;Oral glucose tolerance test&lt;/td&gt;&#xD;&#xA;            &lt;td valign=&quot;top&quot;&gt;Before and 2 hours after a 75 gram oral glucose load is taken orally, the plasma glucose is measured. If this is greater than 11.1 mmol/L, diabetes is likely. If the 2 hour plasma glucose is between 7.8 and 11.0 mmol/L, there is impaired glucose tolerance. If it is less than 7.8 mmol/L, diabetes is unlikely.&lt;/td&gt;&#xD;&#xA;            &lt;td valign=&quot;top&quot;&gt;NHMRC, 2005&lt;/td&gt;&#xD;&#xA;        &lt;/tr&gt;&#xD;&#xA;        &lt;tr&gt;&#xD;&#xA;            &lt;td valign=&quot;top&quot;&gt;Diabetes risk (Australian Type 2 Diabetes Risk Assessment Tool [AUSDRISK])&lt;/td&gt;&#xD;&#xA;            &lt;td valign=&quot;top&quot;&gt;Diabetes risk may be calculated using AUSDRISK. This calculates a score related to the risk of developing diabetes over a 5-year period (see Appendix 4 in the original guideline document).&lt;/td&gt;&#xD;&#xA;            &lt;td valign=&quot;top&quot;&gt;International Diabetes Institute, 2008&lt;/td&gt;&#xD;&#xA;        &lt;/tr&gt;&#xD;&#xA;        &lt;tr&gt;&#xD;&#xA;            &lt;td valign=&quot;top&quot;&gt;Glycated haemoglobin (HbA1c)&lt;/td&gt;&#xD;&#xA;            &lt;td valign=&quot;top&quot;&gt;HbA1c may be used to as a diagnostic test for diabetes. HbA1c of 6.5% is the diagnostic cut-off. However, this is not currently approved by the Medicare Benefits Schedule (MBS) as a test to diagnose diabetes in Australia.&lt;/td&gt;&#xD;&#xA;            &lt;td valign=&quot;top&quot;&gt;Lee &amp;amp; Safranek, 2006; Bennett, Guo, &amp;amp; Dharmage, 2007&lt;/td&gt;&#xD;&#xA;        &lt;/tr&gt;&#xD;&#xA;    &lt;/tbody&gt;&#xD;&#xA;&lt;/table&gt;&#xD;&#xA;&lt;p&gt;&lt;strong&gt;Type 2 Diabetes: Preventive Interventions&lt;/strong&gt;&lt;/p&gt;&#xD;&#xA;&lt;table border=&quot;1&quot; cellspacing=&quot;1&quot; cellpadding=&quot;3&quot; summary=&quot;Table: Type 2 Diabetes: Preventive Interventions&quot;&gt;&#xD;&#xA;    &lt;thead&gt;&#xD;&#xA;        &lt;tr&gt;&#xD;&#xA;            &lt;th valign=&quot;top&quot;&gt;Target Group&lt;/th&gt;&#xD;&#xA;            &lt;th valign=&quot;top&quot;&gt;Intervention&lt;/th&gt;&#xD;&#xA;            &lt;th valign=&quot;top&quot;&gt;References&lt;/th&gt;&#xD;&#xA;        &lt;/tr&gt;&#xD;&#xA;    &lt;/thead&gt;&#xD;&#xA;    &lt;tbody&gt;&#xD;&#xA;        &lt;tr&gt;&#xD;&#xA;            &lt;td valign=&quot;top&quot;&gt;Pre-diabetes (impaired glucose tolerance, impaired fasting glycaemia, gestational diabetes) and those with an elevated Australian Type 2 Diabetes Risk Assessment Tool (AUSDRISK) score or with other specific risk factors with negative screening test.&lt;/td&gt;&#xD;&#xA;            &lt;td valign=&quot;top&quot;&gt;&#xD;&#xA;            &lt;ul style=&quot;list-style-type: disc;&quot;&gt;&#xD;&#xA;                &lt;li&gt;Increasing physical activity (e.g., 30 minutes brisk walking five times a week) and/or weight loss reduces risk of developing diabetes by 40%&amp;ndash;60% in those at high risk. &lt;/li&gt;&#xD;&#xA;                &lt;li&gt;Give advice on healthy low fat diet (&amp;lt;30% kcal or kilojoules from fat and &amp;lt;10% from saturated fat; high fibre, low glycaemic index with cereals, legumes, vegetables and fruits), weight loss and increased physical activity (see &lt;a href=&quot;http://www.racgp.org.au/your-practice/guidelines/snap/&quot; title=&quot;RACGP Web site&quot;&gt;The Royal Australian College of General Practitioners smoking, nutrition, alcohol, physical activity [RACGP SNAP]: A population health guide to behavioural risk factors in general practice&lt;/a&gt;) &lt;/li&gt;&#xD;&#xA;                &lt;li&gt;Refer patients to a dietitian and a physical activity program. &lt;/li&gt;&#xD;&#xA;                &lt;li&gt;Provide pre-conception advice to women with a history of gestational diabetes. &lt;/li&gt;&#xD;&#xA;            &lt;/ul&gt;&#xD;&#xA;            &lt;/td&gt;&#xD;&#xA;            &lt;td valign=&quot;top&quot;&gt;Williamson, Vinicor, &amp;amp; Bowman, 2004; Knowler et al., 2002; Pan et al., 1997; Tuomilehto et al., 2001&lt;/td&gt;&#xD;&#xA;        &lt;/tr&gt;&#xD;&#xA;    &lt;/tbody&gt;&#xD;&#xA;&lt;/table&gt;&#xD;&#xA;&lt;p&gt;&lt;strong&gt;&lt;span style=&quot;text-decoration: underline;&quot;&gt;Stroke&lt;/span&gt;&lt;/strong&gt;&lt;/p&gt;&#xD;&#xA;&lt;p&gt;General practitioners (GP) should be alert to symptoms of transient ischaemic attacks (TIAs) in those aged 45 years and older and assess early in order to prioritise those needing urgent investigation and management. Adults with atrial fibrillation (AF) should have their absolute cardiovascular risk assessed. Patients with AF are at additional risk of thromboembolic disease and stroke (Wolf, Abbot, &amp;amp; Kannel, 1991).&lt;/p&gt;&#xD;&#xA;&lt;p&gt;&lt;strong&gt;Stroke: Identifying Risk&lt;/strong&gt;&lt;/p&gt;&#xD;&#xA;&lt;table border=&quot;1&quot; cellspacing=&quot;1&quot; cellpadding=&quot;3&quot; summary=&quot;Table: Stroke: Identifying Risk&quot;&gt;&#xD;&#xA;    &lt;thead&gt;&#xD;&#xA;        &lt;tr&gt;&#xD;&#xA;            &lt;th valign=&quot;top&quot;&gt;Who Is at Risk?&lt;/th&gt;&#xD;&#xA;            &lt;th valign=&quot;top&quot;&gt;What Should Be Done?&lt;/th&gt;&#xD;&#xA;            &lt;th valign=&quot;top&quot;&gt;How Often?&lt;/th&gt;&#xD;&#xA;            &lt;th valign=&quot;top&quot;&gt;References&lt;/th&gt;&#xD;&#xA;        &lt;/tr&gt;&#xD;&#xA;    &lt;/thead&gt;&#xD;&#xA;    &lt;tbody&gt;&#xD;&#xA;        &lt;tr&gt;&#xD;&#xA;            &lt;td valign=&quot;top&quot;&gt;&lt;strong&gt;High Absolute Risk&lt;/strong&gt;&#xD;&#xA;            &lt;ul style=&quot;list-style-type: disc;&quot;&gt;&#xD;&#xA;                &lt;li&gt;Either calculated &amp;gt;15% absolute risk, clinical determined high risk or pre-existing cardiovascular disease (CVD) &lt;/li&gt;&#xD;&#xA;                &lt;li&gt;Previous stroke (especially with coexistent atrial fibrillation [AF] or high grade [70%&amp;ndash;99%] symptomatic carotid stenosis) &lt;/li&gt;&#xD;&#xA;                &lt;li&gt;Previous transient ischaemic attack (TIA) &lt;/li&gt;&#xD;&#xA;            &lt;/ul&gt;&#xD;&#xA;            &lt;/td&gt;&#xD;&#xA;            &lt;td valign=&quot;top&quot;&gt;Question about symptoms of TIA. If TIA, stratify risk of stroke and consider anticoagulation.* (&lt;strong&gt;I,A&lt;/strong&gt;)&lt;br /&gt;&#xD;&#xA;            &lt;br /&gt;&#xD;&#xA;            If AF, determine cause of AF and treat according to cardiovascular and thromboembolic risk. (&lt;strong&gt;II,B&lt;/strong&gt;) &lt;br /&gt;&#xD;&#xA;            &lt;br /&gt;&#xD;&#xA;            Manage behavioural and physiological risk factors actively. Treat with antihypertensive and lipid-lowering medications unless contraindicated or clinically inappropriate. (&lt;strong&gt;II,B&lt;/strong&gt;)&lt;/td&gt;&#xD;&#xA;            &lt;td valign=&quot;top&quot;&gt;Every 12 months (&lt;strong&gt;IV,C&lt;/strong&gt;)&lt;/td&gt;&#xD;&#xA;            &lt;td valign=&quot;top&quot;&gt;National Vascular Disease Prevention Alliance, 2012; NSF, 2010&lt;br /&gt;&#xD;&#xA;            &lt;br /&gt;&#xD;&#xA;            For stroke/TIA: Goldstein et al., 2006; Hankey, 2001; &quot;Management of patients with stroke,&quot; 2008&lt;/td&gt;&#xD;&#xA;        &lt;/tr&gt;&#xD;&#xA;        &lt;tr&gt;&#xD;&#xA;            &lt;td valign=&quot;top&quot; rowspan=&quot;3&quot;&gt;&lt;strong&gt;Auscultation for Carotid Bruit&lt;/strong&gt;&lt;/td&gt;&#xD;&#xA;            &lt;td valign=&quot;top&quot;&gt;Auscultating for carotid bruits in asymptomatic people is not recommended in the general adult population as a screening tool for stroke risk. Screening with duplex ultrasonography in this population is not cost-effective (yields many false positive results) coupled with the fact that the overall benefit of surgery is at best small, hence very careful selection of patients is needed to justify surgery in those with severe (&amp;gt;60%) but asymptomatic stenosis.&amp;dagger; &lt;/td&gt;&#xD;&#xA;            &lt;td valign=&quot;top&quot; rowspan=&quot;3&quot;&gt;&amp;nbsp;&lt;/td&gt;&#xD;&#xA;            &lt;td valign=&quot;top&quot;&gt;Floriani et al., 1988; Sauve et al., 1994; Goldstein et al., 2006&lt;/td&gt;&#xD;&#xA;        &lt;/tr&gt;&#xD;&#xA;        &lt;tr&gt;&#xD;&#xA;            &lt;td valign=&quot;top&quot;&gt;However, the presence of a carotid bruit has been shown to be associated with increased risk of myocardial infarction and cardiovascular death, so may be a useful prognostic marker when assessing cardiovascular risk generally. &lt;/td&gt;&#xD;&#xA;            &lt;td valign=&quot;top&quot;&gt;Pickett et al., 2008&lt;/td&gt;&#xD;&#xA;        &lt;/tr&gt;&#xD;&#xA;        &lt;tr&gt;&#xD;&#xA;            &lt;td valign=&quot;top&quot;&gt;Screen patients with known asymptomatic carotid artery stenosis for other treatable causes of stroke and treat these intensively.&lt;/td&gt;&#xD;&#xA;            &lt;td valign=&quot;top&quot;&gt;&amp;nbsp;&lt;/td&gt;&#xD;&#xA;        &lt;/tr&gt;&#xD;&#xA;    &lt;/tbody&gt;&#xD;&#xA;&lt;/table&gt;&#xD;&#xA;&lt;p class=&quot;Note&quot;&gt;*Anticoagulation with warfarin should be considered in patients with documented ischaemic stroke or TIAs due to AF.&lt;/p&gt;&#xD;&#xA;&lt;p class=&quot;Note&quot;&gt;&amp;dagger;Antiplatelet therapy should be considered for non-cardioembolic stroke or TIA.&lt;/p&gt;&#xD;&#xA;&lt;p&gt;&lt;strong&gt;Tests to Detect Stroke Risk&lt;/strong&gt;&lt;/p&gt;&#xD;&#xA;&lt;table border=&quot;1&quot; cellspacing=&quot;1&quot; cellpadding=&quot;3&quot; summary=&quot;Table: Tests to Detect Stroke Risk&quot;&gt;&#xD;&#xA;    &lt;thead&gt;&#xD;&#xA;        &lt;tr&gt;&#xD;&#xA;            &lt;th valign=&quot;top&quot;&gt;Test&lt;/th&gt;&#xD;&#xA;            &lt;th valign=&quot;top&quot;&gt;Technique&lt;/th&gt;&#xD;&#xA;            &lt;th valign=&quot;top&quot;&gt;Reference&lt;/th&gt;&#xD;&#xA;        &lt;/tr&gt;&#xD;&#xA;    &lt;/thead&gt;&#xD;&#xA;    &lt;tbody&gt;&#xD;&#xA;        &lt;tr&gt;&#xD;&#xA;            &lt;td valign=&quot;top&quot;&gt;Question about transient ischaemic attack (TIA)&lt;br /&gt;&#xD;&#xA;            ABCD2 tool&lt;/td&gt;&#xD;&#xA;            &lt;td valign=&quot;top&quot;&gt;Question patient or carer regarding symptoms of sudden onset of loss of focal neurological function such as weakness or numbness of arms or legs, speech disturbance, double vision or vertigo.&lt;br /&gt;&#xD;&#xA;            &lt;br /&gt;&#xD;&#xA;            All patients with suspected TIA should have stroke risk assessment including the ABCD2 tool:&#xD;&#xA;            &lt;ul style=&quot;list-style-type: disc;&quot;&gt;&#xD;&#xA;                &lt;li&gt;&lt;strong&gt;A&lt;/strong&gt;ge: &amp;gt;60 years (1 point) &lt;/li&gt;&#xD;&#xA;                &lt;li&gt;&lt;strong&gt;B&lt;/strong&gt;P: &amp;gt;140/90 mmHg (1 point) &lt;/li&gt;&#xD;&#xA;                &lt;li&gt;&lt;strong&gt;C&lt;/strong&gt;linical features: unilateral weakness (2 points), speech impairment without weakness (1 point) &lt;/li&gt;&#xD;&#xA;                &lt;li&gt;&lt;strong&gt;D&lt;/strong&gt;uration: &amp;gt;60 min (2 points), 10&amp;ndash;59 min (1 point) &lt;/li&gt;&#xD;&#xA;                &lt;li&gt;&lt;strong&gt;D&lt;/strong&gt;iabetes (1 point) &lt;/li&gt;&#xD;&#xA;            &lt;/ul&gt;&#xD;&#xA;            Important additional information also required:&#xD;&#xA;            &lt;ul style=&quot;list-style-type: disc;&quot;&gt;&#xD;&#xA;                &lt;li&gt;Presence of atrial fibrillation (AF), signs that might indicate carotid disease (e.g., anterior circulation signs) who are candidates for carotid surgery or 2 or more TIAs within previous 7 days (crescendo TIA) &lt;/li&gt;&#xD;&#xA;            &lt;/ul&gt;&#xD;&#xA;            For those deemed high risk (ABCD2 tool 4&amp;ndash;7 and/or AF, potential carotid disease or crescendo TIA): urgent brain and carotid imaging ('urgent' is considered immediately, but certainly within 24 hours). If carotid territory symptoms, consider duplex ultrasound for patients who are potential candidates for carotid revascularisation. &lt;br /&gt;&#xD;&#xA;            &lt;br /&gt;&#xD;&#xA;            For those deemed high risk (ABCD2 tool 0&amp;ndash;3 without AF, potential carotid disease or crescendo TIA): computed tomography (CT) brain (and carotid ultrasound where indicated) as soon as possible (i.e., within 48&amp;ndash;72 hours).&lt;/td&gt;&#xD;&#xA;            &lt;td valign=&quot;top&quot;&gt;NSF, 2010&lt;/td&gt;&#xD;&#xA;        &lt;/tr&gt;&#xD;&#xA;    &lt;/tbody&gt;&#xD;&#xA;&lt;/table&gt;&#xD;&#xA;&lt;p&gt;For further information about secondary prevention after stroke or TIA, see &lt;a href=&quot;http://www.strokefoundation.com.au&quot; title=&quot;Stroke Foundation of Australia Web site&quot;&gt;www.strokefoundation.com.au&lt;/a&gt;.&lt;/p&gt;&#xD;&#xA;&lt;p&gt;See also the NGC summary of the RACGP guideline &lt;a href=&quot;/content.aspx?id=43861&quot; title=&quot;Guideline #9653&quot;&gt;Screening tests of unproven benefit&lt;/a&gt;.&lt;/p&gt;&#xD;&#xA;&lt;p&gt;&lt;strong&gt;&lt;span style=&quot;text-decoration: underline;&quot;&gt;Kidney Disease&lt;/span&gt;&lt;/strong&gt;&lt;/p&gt;&#xD;&#xA;&lt;p&gt;Patients should be screened for kidney disease if they are at high risk (&lt;strong&gt;B&lt;/strong&gt;).&lt;/p&gt;&#xD;&#xA;&lt;p&gt;&lt;strong&gt;Kidney Disease: Identifying Risk&lt;/strong&gt;&lt;/p&gt;&#xD;&#xA;&lt;table border=&quot;1&quot; cellspacing=&quot;1&quot; cellpadding=&quot;3&quot; summary=&quot;Table: Kidney Disease: Identifying Risk&quot;&gt;&#xD;&#xA;    &lt;thead&gt;&#xD;&#xA;        &lt;tr&gt;&#xD;&#xA;            &lt;th valign=&quot;top&quot;&gt;Who Is at Risk?&lt;/th&gt;&#xD;&#xA;            &lt;th valign=&quot;top&quot;&gt;What Should Be Done?&lt;/th&gt;&#xD;&#xA;            &lt;th valign=&quot;top&quot;&gt;How Often?&lt;/th&gt;&#xD;&#xA;            &lt;th valign=&quot;top&quot;&gt;References&lt;/th&gt;&#xD;&#xA;        &lt;/tr&gt;&#xD;&#xA;    &lt;/thead&gt;&#xD;&#xA;    &lt;tbody&gt;&#xD;&#xA;        &lt;tr&gt;&#xD;&#xA;            &lt;td valign=&quot;top&quot;&gt;&lt;strong&gt;High Risk&lt;/strong&gt;&#xD;&#xA;            &lt;ul style=&quot;list-style-type: disc;&quot;&gt;&#xD;&#xA;                &lt;li&gt;Smoking &amp;ge;40 years &lt;/li&gt;&#xD;&#xA;                &lt;li&gt;Hypertension &lt;/li&gt;&#xD;&#xA;                &lt;li&gt;Obesity &lt;/li&gt;&#xD;&#xA;                &lt;li&gt;Family history of kidney disease &lt;/li&gt;&#xD;&#xA;                &lt;li&gt;Diabetes &lt;/li&gt;&#xD;&#xA;                &lt;li&gt;Aboriginal or Torres Strait Islander aged &amp;gt;30 years &lt;/li&gt;&#xD;&#xA;            &lt;/ul&gt;&#xD;&#xA;            &lt;/td&gt;&#xD;&#xA;            &lt;td valign=&quot;top&quot;&gt;Blood pressure (BP), albumin-creatinine ratio (ACR) and estimated glomerular filtration rate (eGFR) (&lt;strong&gt;III,A&lt;/strong&gt;)&lt;br /&gt;&#xD;&#xA;            &lt;br /&gt;&#xD;&#xA;            If ACR positive, arrange 2 further samples for urine ACR over 2 months. (&lt;strong&gt;III,B&lt;/strong&gt;)&lt;/td&gt;&#xD;&#xA;            &lt;td valign=&quot;top&quot;&gt;Every 1&amp;ndash;2 years* (&lt;strong&gt;IV,C&lt;/strong&gt;)&lt;/td&gt;&#xD;&#xA;            &lt;td valign=&quot;top&quot;&gt;Hoy et al., 1998; Wang et al., 2008; Chadban et al., 2003; Johnson, 2004; Fox et al., 2004; Di Angelantonio et al., 2010; Hallan et al., 2006; Astor et al., 2008; Crowe, Halpin, &amp;amp; Stevens, 2008; Iseki et al., 2003; Eknoyan et al., 2003; Bleyer et al., 2000; Methven et al., 2011; Levey et al., 2003; NHMRC, 2005; Scottish Intercollegiate Guidelines Network (SIGN), 2008; Kidney Health Australia (KHA), 2007; KHA, 2006&lt;/td&gt;&#xD;&#xA;        &lt;/tr&gt;&#xD;&#xA;    &lt;/tbody&gt;&#xD;&#xA;&lt;/table&gt;&#xD;&#xA;&lt;p class=&quot;Note&quot;&gt;*1 year for patients with hypertension or diabetes.&lt;/p&gt;&#xD;&#xA;&lt;p&gt;&lt;strong&gt;Tests to Detect Kidney Disease&lt;/strong&gt;&lt;/p&gt;&#xD;&#xA;&lt;table border=&quot;1&quot; cellspacing=&quot;1&quot; cellpadding=&quot;3&quot; summary=&quot;Table: Tests to Detect Kidney Disease&quot;&gt;&#xD;&#xA;    &lt;thead&gt;&#xD;&#xA;        &lt;tr&gt;&#xD;&#xA;            &lt;th valign=&quot;top&quot;&gt;Test&lt;/th&gt;&#xD;&#xA;            &lt;th class=&quot;Center&quot; valign=&quot;top&quot; colspan=&quot;3&quot;&gt;Technique&lt;/th&gt;&#xD;&#xA;            &lt;th valign=&quot;top&quot;&gt;References&lt;/th&gt;&#xD;&#xA;        &lt;/tr&gt;&#xD;&#xA;    &lt;/thead&gt;&#xD;&#xA;    &lt;tbody&gt;&#xD;&#xA;        &lt;tr&gt;&#xD;&#xA;            &lt;td valign=&quot;top&quot; rowspan=&quot;2&quot;&gt;Albuminuria&lt;/td&gt;&#xD;&#xA;            &lt;td valign=&quot;top&quot; colspan=&quot;3&quot;&gt;Spot, untimed collection of urine for calculation urine albumin-to-creatinine ratio (UACR), preferably on a first morning void.&lt;br /&gt;&#xD;&#xA;            &lt;br /&gt;&#xD;&#xA;            Note: dipstick urine test is not adequate to identify microalbuminuria.&lt;br /&gt;&#xD;&#xA;            &lt;br /&gt;&#xD;&#xA;            Albumin:creatinine ratio (ACR)&lt;/td&gt;&#xD;&#xA;            &lt;td valign=&quot;top&quot; rowspan=&quot;2&quot;&gt;Eknoyan et al., 2003; Methven et al., 2011&lt;/td&gt;&#xD;&#xA;        &lt;/tr&gt;&#xD;&#xA;        &lt;tr&gt;&#xD;&#xA;            &lt;td valign=&quot;top&quot;&gt;&lt;br /&gt;&#xD;&#xA;            Normal&lt;br /&gt;&#xD;&#xA;            Microalbuminuria&lt;br /&gt;&#xD;&#xA;            Macroalbuminuria&lt;/td&gt;&#xD;&#xA;            &lt;td valign=&quot;top&quot;&gt;Females&lt;br /&gt;&#xD;&#xA;            &amp;lt;3.5 mg/mmol&lt;br /&gt;&#xD;&#xA;            3.5&amp;ndash;35 mg/mmol&lt;br /&gt;&#xD;&#xA;            &amp;gt;35 mg/mmol&lt;/td&gt;&#xD;&#xA;            &lt;td valign=&quot;top&quot;&gt;Males&lt;br /&gt;&#xD;&#xA;            &amp;lt;2.5 mg/mmol&lt;br /&gt;&#xD;&#xA;            2.5&amp;ndash;25 mg/mmol&lt;br /&gt;&#xD;&#xA;            &amp;gt;25 mg/mmol&lt;/td&gt;&#xD;&#xA;        &lt;/tr&gt;&#xD;&#xA;        &lt;tr&gt;&#xD;&#xA;            &lt;td valign=&quot;top&quot;&gt;Glomerular filtration rate (GFR)&lt;/td&gt;&#xD;&#xA;            &lt;td valign=&quot;top&quot; colspan=&quot;3&quot;&gt;This is currently automatically reported with every test for serum creatinine using the abbreviated modification of diet in renal disease formula (staging is based on both GFR level and UACR (normoalbuminuria, microalbuminuria or macroalbuminuria):&#xD;&#xA;            &lt;ul style=&quot;list-style-type: disc;&quot;&gt;&#xD;&#xA;                &lt;li&gt;Stage 1 &amp;gt;90 mL/min/1.73 m&lt;sup&gt;2&lt;/sup&gt; with microalbuminuria, proteinuria or haematuria &lt;/li&gt;&#xD;&#xA;                &lt;li&gt;Stage 2 (mild) 60&amp;ndash;89 mL/min/1.73 m&lt;sup&gt;2&lt;/sup&gt; with microalbuminuria, proteinuria or haematuria &lt;/li&gt;&#xD;&#xA;                &lt;li&gt;Stage 3a (mod) 45&amp;ndash;59 mL/min/1.73 m&lt;sup&gt;2&lt;/sup&gt; &lt;/li&gt;&#xD;&#xA;                &lt;li&gt;Stage 3b (mod) 30&amp;ndash;44 mL/min/1.73 m&lt;sup&gt;2&lt;/sup&gt; &lt;/li&gt;&#xD;&#xA;                &lt;li&gt;Stage 4 (severe) 15&amp;ndash;29 mL/min/1.73 m&lt;sup&gt;2&lt;/sup&gt; &lt;/li&gt;&#xD;&#xA;                &lt;li&gt;Stage 5 (end-stage) &amp;lt;15 mL/min/1.73 m&lt;sup&gt;2&lt;/sup&gt; &lt;/li&gt;&#xD;&#xA;            &lt;/ul&gt;&#xD;&#xA;            Refer patients with stage 4 or 5 to renal unit or nephrologist, and consider referral at stage 3 or earlier if:&#xD;&#xA;            &lt;ul style=&quot;list-style-type: disc;&quot;&gt;&#xD;&#xA;                &lt;li&gt;Persistent significant albuminuria (ACR &amp;ge;30 mg/mmol, approximately equivalent to protein:creatinine ratio &amp;ge;50 mg/mmol, or urinary protein excretion &amp;ge;500 mg/24 hours) &lt;/li&gt;&#xD;&#xA;                &lt;li&gt;Rapidly declining estimated glomerular filtration rate (eGFR) (average [of at least three readings] decline &amp;gt;5 mL/min/1.73 m&lt;sup&gt;2&lt;/sup&gt; in 6 months) &lt;/li&gt;&#xD;&#xA;                &lt;li&gt;Chronic kidney disease (CKD) and hypertension that is hard to get to target despite at least 3 anti-hypertensive agents &lt;/li&gt;&#xD;&#xA;                &lt;li&gt;Unexplained anaemia (&amp;lt;100 g/L) with eGFR &amp;lt;60mL/min/1.73m&lt;sup&gt;2&lt;/sup&gt; &lt;/li&gt;&#xD;&#xA;            &lt;/ul&gt;&#xD;&#xA;            The eGFR may be unreliable in the following situations:&#xD;&#xA;            &lt;ul style=&quot;list-style-type: disc;&quot;&gt;&#xD;&#xA;                &lt;li&gt;Acute changes in renal function &lt;/li&gt;&#xD;&#xA;                &lt;li&gt;Dialysis patients &lt;/li&gt;&#xD;&#xA;                &lt;li&gt;Certain diets (e.g., vegetarian, high protein, recent ingestion of cooked meat) &lt;/li&gt;&#xD;&#xA;                &lt;li&gt;Extremes of body size &lt;/li&gt;&#xD;&#xA;                &lt;li&gt;Muscle diseases (may overestimate) or high muscle mass (may underestimate) &lt;/li&gt;&#xD;&#xA;                &lt;li&gt;Children &amp;lt;18 years &lt;/li&gt;&#xD;&#xA;                &lt;li&gt;Severe liver disease &lt;/li&gt;&#xD;&#xA;            &lt;/ul&gt;&#xD;&#xA;            It has not been validated in all ethnic groups.&lt;/td&gt;&#xD;&#xA;            &lt;td valign=&quot;top&quot;&gt;Levey et al., 2003; KHA, 2007; Levey et al., 2009&lt;/td&gt;&#xD;&#xA;        &lt;/tr&gt;&#xD;&#xA;    &lt;/tbody&gt;&#xD;&#xA;&lt;/table&gt;&#xD;&#xA;&lt;p&gt;&lt;strong&gt;&lt;span style=&quot;text-decoration: underline;&quot;&gt;Definitions&lt;/span&gt;&lt;/strong&gt;:&lt;/p&gt;&#xD;&#xA;&lt;p&gt;&lt;strong&gt;Levels of Evidence&lt;/strong&gt;&lt;/p&gt;&#xD;&#xA;&lt;table border=&quot;1&quot; cellspacing=&quot;1&quot; cellpadding=&quot;3&quot; summary=&quot;Table: Levels of Evidence&quot;&gt;&#xD;&#xA;    &lt;thead&gt;&#xD;&#xA;        &lt;tr&gt;&#xD;&#xA;            &lt;th valign=&quot;top&quot;&gt;Level&lt;/th&gt;&#xD;&#xA;            &lt;th valign=&quot;top&quot;&gt;Explanation&lt;/th&gt;&#xD;&#xA;        &lt;/tr&gt;&#xD;&#xA;    &lt;/thead&gt;&#xD;&#xA;    &lt;tbody&gt;&#xD;&#xA;        &lt;tr&gt;&#xD;&#xA;            &lt;td valign=&quot;top&quot;&gt;I&lt;/td&gt;&#xD;&#xA;            &lt;td valign=&quot;top&quot;&gt;Evidence obtained from a systematic review of level II studies&lt;/td&gt;&#xD;&#xA;        &lt;/tr&gt;&#xD;&#xA;        &lt;tr&gt;&#xD;&#xA;            &lt;td valign=&quot;top&quot;&gt;II&lt;/td&gt;&#xD;&#xA;            &lt;td valign=&quot;top&quot;&gt;Evidence obtained from a randomised controlled trial (RCT)&lt;/td&gt;&#xD;&#xA;        &lt;/tr&gt;&#xD;&#xA;        &lt;tr&gt;&#xD;&#xA;            &lt;td valign=&quot;top&quot;&gt;III&amp;ndash;1&lt;/td&gt;&#xD;&#xA;            &lt;td valign=&quot;top&quot;&gt;Evidence obtained from a pseudo-randomised controlled trial (i.e., alternate allocation or some other method)&lt;/td&gt;&#xD;&#xA;        &lt;/tr&gt;&#xD;&#xA;        &lt;tr&gt;&#xD;&#xA;            &lt;td valign=&quot;top&quot;&gt;III&amp;ndash;2&lt;/td&gt;&#xD;&#xA;            &lt;td valign=&quot;top&quot;&gt;Evidence obtained from a comparative study with concurrent controls:&#xD;&#xA;            &lt;ul style=&quot;list-style-type: disc;&quot;&gt;&#xD;&#xA;                &lt;li&gt;Non-randomised, experimental trial &lt;/li&gt;&#xD;&#xA;                &lt;li&gt;Cohort study &lt;/li&gt;&#xD;&#xA;                &lt;li&gt;Case&amp;ndash;control study &lt;/li&gt;&#xD;&#xA;                &lt;li&gt;Interrupted time series with a control group &lt;/li&gt;&#xD;&#xA;            &lt;/ul&gt;&#xD;&#xA;            &lt;/td&gt;&#xD;&#xA;        &lt;/tr&gt;&#xD;&#xA;        &lt;tr&gt;&#xD;&#xA;            &lt;td valign=&quot;top&quot;&gt;III&amp;ndash;3&lt;/td&gt;&#xD;&#xA;            &lt;td valign=&quot;top&quot;&gt;Evidence obtained from a comparative study without concurrent controls:&#xD;&#xA;            &lt;ul style=&quot;list-style-type: disc;&quot;&gt;&#xD;&#xA;                &lt;li&gt;Historical control study &lt;/li&gt;&#xD;&#xA;                &lt;li&gt;Two or more single arm study &lt;/li&gt;&#xD;&#xA;                &lt;li&gt;Interrupted time series without a parallel control group &lt;/li&gt;&#xD;&#xA;            &lt;/ul&gt;&#xD;&#xA;            &lt;/td&gt;&#xD;&#xA;        &lt;/tr&gt;&#xD;&#xA;        &lt;tr&gt;&#xD;&#xA;            &lt;td valign=&quot;top&quot;&gt;IV&lt;/td&gt;&#xD;&#xA;            &lt;td valign=&quot;top&quot;&gt;Case series with either post-test or pre-test/post-test outcomes&lt;/td&gt;&#xD;&#xA;        &lt;/tr&gt;&#xD;&#xA;        &lt;tr&gt;&#xD;&#xA;            &lt;td valign=&quot;top&quot;&gt;Practice Point&lt;/td&gt;&#xD;&#xA;            &lt;td valign=&quot;top&quot;&gt;Opinions of respected authorities, based on clinical experience, descriptive studies or reports of expert committees&lt;/td&gt;&#xD;&#xA;        &lt;/tr&gt;&#xD;&#xA;    &lt;/tbody&gt;&#xD;&#xA;&lt;/table&gt;&#xD;&#xA;&lt;p&gt;&lt;strong&gt;Grades of Recommendations&lt;/strong&gt;&lt;/p&gt;&#xD;&#xA;&lt;table border=&quot;1&quot; cellspacing=&quot;1&quot; cellpadding=&quot;3&quot; summary=&quot;Table: Grades of Recommendations&quot;&gt;&#xD;&#xA;    &lt;thead&gt;&#xD;&#xA;        &lt;tr&gt;&#xD;&#xA;            &lt;th valign=&quot;top&quot;&gt;Grade&lt;/th&gt;&#xD;&#xA;            &lt;th valign=&quot;top&quot;&gt;Explanation&lt;/th&gt;&#xD;&#xA;        &lt;/tr&gt;&#xD;&#xA;    &lt;/thead&gt;&#xD;&#xA;    &lt;tbody&gt;&#xD;&#xA;        &lt;tr&gt;&#xD;&#xA;            &lt;td valign=&quot;top&quot;&gt;A&lt;/td&gt;&#xD;&#xA;            &lt;td valign=&quot;top&quot;&gt;Body of evidence can be trusted to guide practice&lt;/td&gt;&#xD;&#xA;        &lt;/tr&gt;&#xD;&#xA;        &lt;tr&gt;&#xD;&#xA;            &lt;td valign=&quot;top&quot;&gt;B&lt;/td&gt;&#xD;&#xA;            &lt;td valign=&quot;top&quot;&gt;Body of evidence can be trusted to guide practice in most situations&lt;/td&gt;&#xD;&#xA;        &lt;/tr&gt;&#xD;&#xA;        &lt;tr&gt;&#xD;&#xA;            &lt;td valign=&quot;top&quot;&gt;C&lt;/td&gt;&#xD;&#xA;            &lt;td valign=&quot;top&quot;&gt;Body of evidence provides some support for recommendation(s) but care should be taken in its application&lt;/td&gt;&#xD;&#xA;        &lt;/tr&gt;&#xD;&#xA;        &lt;tr&gt;&#xD;&#xA;            &lt;td valign=&quot;top&quot;&gt;D&lt;/td&gt;&#xD;&#xA;            &lt;td valign=&quot;top&quot;&gt;Body of evidence is weak and recommendation must be applied with caution&lt;/td&gt;&#xD;&#xA;        &lt;/tr&gt;&#xD;&#xA;    &lt;/tbody&gt;&#xD;&#xA;&lt;/table&gt;&lt;/div&gt;" /></Field><Field FieldID="138" OrdBy="515" ID="423" Name="Clinical Algorithm(s)" Type="text"><FieldValue Value="&lt;div class=&quot;content_para&quot;&gt;&lt;p&gt;None provided&lt;/p&gt;&lt;/div&gt;" /></Field></Section><Section SecID="424" OrdBy="600" Name="Evidence Supporting the Recommendations"><Field FieldID="98" OrdBy="605" ID="425" Name="References Supporting the Recommendations" Type="citation"><FieldValue Value="&lt;table&gt;&lt;tr&gt;&lt;td&gt;Astor BC, Hallan SI, Miller ER 3rd, Yeung E, Coresh J. Glomerular filtration rate, albuminuria, and risk of cardiovascular and all-cause mortality in the US population. Am J Epidemiol. 2008 May 15;167(10):1226-34. &lt;a href=&quot;http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=18385206&quot; target=&quot;_blank&quot;&gt;PubMed&lt;/a&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;" /><FieldValue Value="&lt;table&gt;&lt;tr&gt;&lt;td&gt;Australian Institute of Health and Welfare. The health and welfare of Australia's Aboriginal and Torres Strait Islander peoples. Canberra: AIHW; 2001. &lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;" /><FieldValue Value="&lt;table&gt;&lt;tr&gt;&lt;td&gt;Bachorik PS, Cloey TA, Finney CA, Lowry DR, Becker DM. Lipoprotein-cholesterol analysis during screening: accuracy and reliability. Ann Intern Med. 1991 May 1;114(9):741-7. &lt;a href=&quot;http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=2012356&quot; target=&quot;_blank&quot;&gt;PubMed&lt;/a&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;" /><FieldValue Value="&lt;table&gt;&lt;tr&gt;&lt;td&gt;Bennett CM, Guo M, Dharmage SC. HbA(1c) as a screening tool for detection of Type 2 diabetes: a systematic review. Diabet Med. 2007 Apr;24(4):333-43. [42 references] &lt;a href=&quot;http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=17367307&quot; target=&quot;_blank&quot;&gt;PubMed&lt;/a&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;" /><FieldValue Value="&lt;table&gt;&lt;tr&gt;&lt;td&gt;Bleyer AJ, Shemanski LR, Burke GL, Hansen KJ, Appel RG. Tobacco, hypertension, and vascular disease: risk factors for renal functional decline in an older population. Kidney Int. 2000 May;57(5):2072-9. &lt;a href=&quot;http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=10792626&quot; target=&quot;_blank&quot;&gt;PubMed&lt;/a&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;" /><FieldValue Value="&lt;table&gt;&lt;tr&gt;&lt;td&gt;Bradford RH, Bachorik PS, Roberts K, Williams OD, Gotto AM Jr. Blood cholesterol screening in several environments using a portable, dry-chemistry analyzer and fingerstick blood samples. Lipid Research Clinics Cholesterol Screening Study Group. Am J Cardiol. 1990 Jan 1;65(1):6-13. &lt;a href=&quot;http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=2294681&quot; target=&quot;_blank&quot;&gt;PubMed&lt;/a&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;" /><FieldValue Value="&lt;table&gt;&lt;tr&gt;&lt;td&gt;Chadban SJ, Briganti EM, Kerr PG, Dunstan DW, Welborn TA, Zimmet PZ, Atkins RC. Prevalence of kidney damage in Australian adults: The AusDiab kidney study. J Am Soc Nephrol. 2003 Jul;14(7 Suppl 2):S131-8. &lt;a href=&quot;http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=12819318&quot; target=&quot;_blank&quot;&gt;PubMed&lt;/a&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;" /><FieldValue Value="&lt;table&gt;&lt;tr&gt;&lt;td&gt;Crowe E, Halpin D, Stevens P, Guideline Development Group. Early identification and management of chronic kidney disease: summary of NICE guidance. BMJ. 2008;337:a1530. &lt;a href=&quot;http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=18824486&quot; target=&quot;_blank&quot;&gt;PubMed&lt;/a&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;" /><FieldValue Value="&lt;table&gt;&lt;tr&gt;&lt;td&gt;Culleton BF, Larson MG, Wilson PW, Evans JC, Parfrey PS, Levy D. Cardiovascular disease and mortality in a community-based cohort with mild renal  insufficiency. Kidney Int. 1999 Dec;56(6):2214-9. &lt;a href=&quot;http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=10594797&quot; target=&quot;_blank&quot;&gt;PubMed&lt;/a&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;" /><FieldValue Value="&lt;table&gt;&lt;tr&gt;&lt;td&gt;Di Angelantonio E, Chowdhury R, Sarwar N, Aspelund T, Danesh J, Gudnason V. Chronic kidney disease and risk of major cardiovascular disease and non-vascular  mortality: prospective population based cohort study. BMJ. 2010;341:c4986. &lt;a href=&quot;http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=20884698&quot; target=&quot;_blank&quot;&gt;PubMed&lt;/a&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;" /><FieldValue Value="&lt;table&gt;&lt;tr&gt;&lt;td&gt;Eknoyan G, Hostetter T, Bakris GL, Hebert L, Levey AS, Parving HH, Steffes MW, Toto R. Proteinuria and other markers of chronic kidney disease: a position statement of  the national kidney foundation (NKF) and the national institute of diabetes and digestive and kidney diseases (NIDDK). Am J Kidney Dis. 2003 Oct;42(4):617-22. [4 references] &lt;a href=&quot;http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=14520612&quot; target=&quot;_blank&quot;&gt;PubMed&lt;/a&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;" /><FieldValue Value="&lt;table&gt;&lt;tr&gt;&lt;td&gt;Floriani M, Giulini SM, Bonardelli S, Portolani N, Benvenuti M, Pouche A, Tiberio G. Value and limits of &quot;critical auscultation&quot; of neck bruits. Angiology. 1988 Nov;39(11):967-72. &lt;a href=&quot;http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=3052185&quot; target=&quot;_blank&quot;&gt;PubMed&lt;/a&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;" /><FieldValue Value="&lt;table&gt;&lt;tr&gt;&lt;td&gt;Fox CS, Larson MG, Leip EP, Culleton B, Wilson PW, Levy D. Predictors of new-onset kidney disease in a community-based population. JAMA. 2004 Feb 18;291(7):844-50. &lt;a href=&quot;http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=14970063&quot; target=&quot;_blank&quot;&gt;PubMed&lt;/a&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;" /><FieldValue Value="&lt;table&gt;&lt;tr&gt;&lt;td&gt;Go AS, Chertow GM, Fan D, McCulloch CE, Hsu CY. Chronic kidney disease and the risks of death, cardiovascular events, and hospitalization. N Engl J Med. 2004 Sep 23;351(13):1296-305. &lt;a href=&quot;http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=15385656&quot; target=&quot;_blank&quot;&gt;PubMed&lt;/a&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;" /><FieldValue Value="&lt;table&gt;&lt;tr&gt;&lt;td&gt;Goldstein LB, Adams R, Alberts MJ, Appel LJ, Brass LM, Bushnell CD, Culebras A, DeGraba TJ, Gorelick PB, Guyton JR, Hart RG, Howard G, Kelly-Hayes M, Nixon JV, Sacco RL, American Heart Association, American Stroke Association Stroke Council. Primary prevention of ischemic stroke: a guideline from the American Heart Association/American Stroke Association Stroke Council [trunc]. Circulation. 2006 Jun 20;113(24):e873-923. &lt;a href=&quot;http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=16785347&quot; target=&quot;_blank&quot;&gt;PubMed&lt;/a&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;" /><FieldValue Value="&lt;table&gt;&lt;tr&gt;&lt;td&gt;Hallan SI, Dahl K, Oien CM, Grootendorst DC, Aasberg A, Holmen J, Dekker FW. Screening strategies for chronic kidney disease in the general population: follow-up of cross sectional health survey. BMJ. 2006 Nov 18;333(7577):1047. &lt;a href=&quot;http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=17062598&quot; target=&quot;_blank&quot;&gt;PubMed&lt;/a&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;" /><FieldValue Value="&lt;table&gt;&lt;tr&gt;&lt;td&gt;Hankey GJ. Non-valvular atrial fibrillation and stroke prevention. National Blood Pressure Advisory Committee of the National Heart Foundation. Med J Aust. 2001 Mar 5;174(5):234-9. [48 references] &lt;a href=&quot;http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=11280695&quot; target=&quot;_blank&quot;&gt;PubMed&lt;/a&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;" /><FieldValue Value="&lt;table&gt;&lt;tr&gt;&lt;td&gt;Hoy WE, Mathews JD, McCredie DA, Pugsley DJ, Hayhurst BG, Rees M, Kile E, Walker KA, Wang Z. The multidimensional nature of renal disease: rates and associations of albuminuria in an Australian Aboriginal community. Kidney Int. 1998 Oct;54(4):1296-304. &lt;a href=&quot;http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=9767547&quot; target=&quot;_blank&quot;&gt;PubMed&lt;/a&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;" /><FieldValue Value="&lt;table&gt;&lt;tr&gt;&lt;td&gt;International Diabetes Institute. The Australian type 2 diabetes risk assessment tool. Canberra: AGDHA; 2008. &lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;" /><FieldValue Value="&lt;table&gt;&lt;tr&gt;&lt;td&gt;Iseki K, Ikemiya Y, Iseki C, Takishita S. Proteinuria and the risk of developing end-stage renal disease. Kidney Int. 2003 Apr;63(4):1468-74. &lt;a href=&quot;http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=12631363&quot; target=&quot;_blank&quot;&gt;PubMed&lt;/a&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;" /><FieldValue Value="&lt;table&gt;&lt;tr&gt;&lt;td&gt;Johnson DW. Evidence-based guide to slowing the progression of early renal insufficiency. Intern Med J. 2004 Jan-Feb;34(1-2):50-7. &lt;a href=&quot;http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=14748914&quot; target=&quot;_blank&quot;&gt;PubMed&lt;/a&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;" /><FieldValue Value="&lt;table&gt;&lt;tr&gt;&lt;td&gt;Kidney Health Australia. Chronic kidney disease (CKD) management in general practice. Melbourne: KHA; 2007. &lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;" /><FieldValue Value="&lt;table&gt;&lt;tr&gt;&lt;td&gt;Kidney Health Australia. National chronic kidney disease strategy. Melbourne: KHA; 2006. &lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;" /><FieldValue Value="&lt;table&gt;&lt;tr&gt;&lt;td&gt;Knowler WC, Barrett-Connor E, Fowler SE, Hamman RF, Lachin JM, Walker EA, Nathan DM. Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin. N Engl J Med. 2002 Feb 7;346(6):393-403. &lt;a href=&quot;http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=11832527&quot; target=&quot;_blank&quot;&gt;PubMed&lt;/a&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;" /><FieldValue Value="&lt;table&gt;&lt;tr&gt;&lt;td&gt;Lee TJ, Safranek S. FPIN's clinical inquiries. A1C testing in the diagnosis of diabetes mellitus. Am Fam Physician. 2006 Jul 1;74(1):143-4. [6 references] &lt;a href=&quot;http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=16848387&quot; target=&quot;_blank&quot;&gt;PubMed&lt;/a&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;" /><FieldValue Value="&lt;table&gt;&lt;tr&gt;&lt;td&gt;Levey AS, Coresh J, Balk E, Kausz AT, Levin A, Steffes MW, Hogg RJ, Perrone RD, Lau J, Eknoyan G, National Kidney Foundation. National Kidney Foundation practice guidelines for chronic kidney disease: evaluation, classification, and stratification. Ann Intern Med. 2003 Jul 15;139(2):137-47. &lt;a href=&quot;http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=12859163&quot; target=&quot;_blank&quot;&gt;PubMed&lt;/a&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;" /><FieldValue Value="&lt;table&gt;&lt;tr&gt;&lt;td&gt;Levey AS, Stevens LA, Schmid CH, Zhang YL, Castro AF 3rd, Feldman HI, Kusek JW, Eggers P, Van Lente F, Greene T, Coresh J, CKD-EPI (Chronic Kidney Disease Epidemiology Collaboration). A new equation to estimate glomerular filtration rate. Ann Intern Med. 2009 May 5;150(9):604-12. &lt;a href=&quot;http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=19414839&quot; target=&quot;_blank&quot;&gt;PubMed&lt;/a&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;" /><FieldValue Value="&lt;table&gt;&lt;tr&gt;&lt;td&gt;Levy PJ, Jackson SA, McCoy TP, Ferrario CM. Clinical characteristics of patients with premature lower extremity atherosclerosis associated with familial early cardiovascular disease and/or cancer. Int Angiol. 2006 Sep;25(3):304-9. &lt;a href=&quot;http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=16878081&quot; target=&quot;_blank&quot;&gt;PubMed&lt;/a&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;" /><FieldValue Value="&lt;table&gt;&lt;tr&gt;&lt;td&gt;Management of patients with stroke or TIA: assessment, investigation, immediate management and secondary prevention. A national clinical guideline. Edinburgh (Scotland): Scottish Intercollegiate Guidelines Network (SIGN); 2008. 103 p.&amp;nbsp;(SIGN publication; no. 108).&amp;nbsp; [300 references]&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;" /><FieldValue Value="&lt;table&gt;&lt;tr&gt;&lt;td&gt;Methven S, MacGregor MS, Traynor JP, Hair M, O'Reilly DS, Deighan CJ. Comparison of urinary albumin and urinary total protein as predictors of patient  outcomes in CKD. Am J Kidney Dis. 2011 Jan;57(1):21-8. &lt;a href=&quot;http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=20951485&quot; target=&quot;_blank&quot;&gt;PubMed&lt;/a&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;" /><FieldValue Value="&lt;table&gt;&lt;tr&gt;&lt;td&gt;National Health and Medical Research Council. National evidence based guidelines for case detection and diagnosis of type 2 diabetes. Canberra: NHMRC; 2009. &lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;" /><FieldValue Value="&lt;table&gt;&lt;tr&gt;&lt;td&gt;National Health and Medical Research Council. National evidence based guidelines for the management of type 2 diabetes mellitus: primary prevention, case detection and diagnosis. Canberra: NHMRC; 2005. &lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;" /><FieldValue Value="&lt;table&gt;&lt;tr&gt;&lt;td&gt;National Heart Foundation of Australia, National Blood Pressure and Vascular Disease Advisory Committee. Guide to management of hypertension 2008. Heart Foundation; 2010 Dec. &lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;" /><FieldValue Value="&lt;table&gt;&lt;tr&gt;&lt;td&gt;National Stroke Foundation. Clinical guidelines for stroke management. Melbourne: NSF; 2010. &lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;" /><FieldValue Value="&lt;table&gt;&lt;tr&gt;&lt;td&gt;National Vascular Disease Prevention Alliance. Guidelines for the assessment of absolute cardiovascular disease risk. Canberra (Australia): National Heart Foundation of Australia; 2009. 49 p.  [118 references]&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;" /><FieldValue Value="&lt;table&gt;&lt;tr&gt;&lt;td&gt;National Vascular Disease Prevention Alliance. Guidelines for the management of absolute cardiovascular disease risk. Heart Foundation; 2012. &lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;" /><FieldValue Value="&lt;table&gt;&lt;tr&gt;&lt;td&gt;Pan XR, Li GW, Hu YH, Wang JX, Yang WY, An ZX, Hu ZX, Lin J, Xiao JZ, Cao HB, Liu PA, Jiang XG, Jiang YY, Wang JP, Zheng H, Zhang H, Bennett PH, Howard BV. Effects of diet and exercise in preventing NIDDM in people with impaired glucose tolerance. The Da Qing IGT and Diabetes Study. Diabetes Care. 1997 Apr;20(4):537-44. &lt;a href=&quot;http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=9096977&quot; target=&quot;_blank&quot;&gt;PubMed&lt;/a&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;" /><FieldValue Value="&lt;table&gt;&lt;tr&gt;&lt;td&gt;Pickett CA, Jackson JL, Hemann BA, Atwood JE. Carotid bruits as a prognostic indicator of cardiovascular death and myocardial infarction: a meta-analysis. Lancet. 2008 May 10;371(9624):1587-94. [49 references] &lt;a href=&quot;http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=18468542&quot; target=&quot;_blank&quot;&gt;PubMed&lt;/a&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;" /><FieldValue Value="&lt;table&gt;&lt;tr&gt;&lt;td&gt;Sauve JS, Thorpe KE, Sackett DL, Taylor W, Barnett HJ, Haynes RB, Fox AJ. Can bruits distinguish high-grade from moderate symptomatic carotid stenosis? The North American Symptomatic Carotid Endarterectomy Trial. Ann Intern Med. 1994 Apr 15;120(8):633-7. &lt;a href=&quot;http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=8135446&quot; target=&quot;_blank&quot;&gt;PubMed&lt;/a&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;" /><FieldValue Value="&lt;table&gt;&lt;tr&gt;&lt;td&gt;Scottish Intercollegiate Guidelines Network (SIGN). Diagnosis and management of chronic kidney disease. A national clinical guideline. Edinburgh (Scotland): Scottish Intercollegiate Guidelines Network (SIGN); 2008. 50 p.&amp;nbsp;(SIGN publication; no. 103).&amp;nbsp; [250 references]&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;" /><FieldValue Value="&lt;table&gt;&lt;tr&gt;&lt;td&gt;Tonkin A, Barter P, Best J, Boyden A, Furler J, Hossack K, Sullivan D, Thompson P, Vale M, Cooper C, Robinson M, Clune E, National Heart Foundation of Australia, Cardiac Society of Australia and New Zealand. National Heart Foundation of Australia and the Cardiac Society of Australia and New Zealand: position statement on lipid management--2005. Heart Lung Circ. 2005 Dec;14(4):275-91. [70 references] &lt;a href=&quot;http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=16361000&quot; target=&quot;_blank&quot;&gt;PubMed&lt;/a&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;" /><FieldValue Value="&lt;table&gt;&lt;tr&gt;&lt;td&gt;Tuomilehto J, Lindstrom J, Eriksson JG, Valle TT, Hamalainen H, Ilanne-Parikka P, Keinanen-Kiukaanniemi S, Laakso M, Louheranta A, Rastas M, Salminen V, Uusitupa M. Prevention of type 2 diabetes mellitus by changes in lifestyle among subjects with impaired glucose tolerance. N Engl J Med. 2001 May 3;344(18):1343-50. &lt;a href=&quot;http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=11333990&quot; target=&quot;_blank&quot;&gt;PubMed&lt;/a&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;" /><FieldValue Value="&lt;table&gt;&lt;tr&gt;&lt;td&gt;U.S. Preventive Services Task Force. Screening for high blood pressure: U.S. Preventive Services Task Force reaffirmation recommendation statement. Ann Intern Med. 2007 Dec 4;147(11):783-6. [6 references] &lt;a href=&quot;http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=18056662&quot; target=&quot;_blank&quot;&gt;PubMed&lt;/a&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;" /><FieldValue Value="&lt;table&gt;&lt;tr&gt;&lt;td&gt;van Dis I, Kromhout D, Geleijnse JM, Boer JM, Verschuren WM. Body mass index and waist circumference predict both 10-year nonfatal and fatal cardiovascular disease risk: study conducted in 20,000 Dutch men and women aged 20-65 years. Eur J Cardiovasc Prev Rehabil. 2009 Dec;16(6):729-34. &lt;a href=&quot;http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=19809330&quot; target=&quot;_blank&quot;&gt;PubMed&lt;/a&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;" /><FieldValue Value="&lt;table&gt;&lt;tr&gt;&lt;td&gt;Vasan RS, Larson MG, Leip EP, Kannel WB, Levy D. Assessment of frequency of progression to hypertension in non-hypertensive participants in the Framingham Heart Study: a cohort study. Lancet. 2001 Nov 17;358(9294):1682-6. &lt;a href=&quot;http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=11728544&quot; target=&quot;_blank&quot;&gt;PubMed&lt;/a&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;" /><FieldValue Value="&lt;table&gt;&lt;tr&gt;&lt;td&gt;Wang Y, Chen X, Song Y, Caballero B, Cheskin LJ. Association between obesity and kidney disease: a systematic review and meta-analysis. Kidney Int. 2008 Jan;73(1):19-33. [87 references] &lt;a href=&quot;http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=17928825&quot; target=&quot;_blank&quot;&gt;PubMed&lt;/a&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;" /><FieldValue Value="&lt;table&gt;&lt;tr&gt;&lt;td&gt;Welborn TA, Dhaliwal SS, Bennett SA. Waist-hip ratio is the dominant risk factor predicting cardiovascular death in Australia. Med J Aust. 2003 Dec 1-15;179(11-12):580-5. &lt;a href=&quot;http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=14636121&quot; target=&quot;_blank&quot;&gt;PubMed&lt;/a&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;" /><FieldValue Value="&lt;table&gt;&lt;tr&gt;&lt;td&gt;Williamson DF, Vinicor F, Bowman BA, Centers For Disease Control And Prevention Primary Prevention Working Group. Primary prevention of type 2 diabetes mellitus by lifestyle intervention: implications for health policy. Ann Intern Med. 2004 Jun 1;140(11):951-7. [56 references] &lt;a href=&quot;http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=15172920&quot; target=&quot;_blank&quot;&gt;PubMed&lt;/a&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;" /><FieldValue Value="&lt;table&gt;&lt;tr&gt;&lt;td&gt;Wolf PA, Abbott RD, Kannel WB. Atrial fibrillation as an independent risk factor for stroke: the Framingham Study. Stroke. 1991 Aug;22(8):983-8. &lt;a href=&quot;http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=1866765&quot; target=&quot;_blank&quot;&gt;PubMed&lt;/a&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;" /></Field><Field FieldID="139" OrdBy="610" ID="426" Name="Type of Evidence Supporting the Recommendations" Type="text"><FieldValue Value="&lt;div class=&quot;content_para&quot;&gt;&lt;p&gt;The type of supporting evidence is identified and graded for selected recommendations (see the &quot;Major Recommendations&quot; field).&lt;/p&gt;&lt;/div&gt;" /></Field></Section><Section SecID="427" OrdBy="700" Name="Benefits/Harms of Implementing the Guideline Recommendations"><Field FieldID="152" OrdBy="705" ID="428" Name="Potential Benefits" Type="text"><FieldValue Value="&lt;div class=&quot;content_para&quot;&gt;&lt;p&gt;Prevention of cardiovascular and metabolic disease by changing behavioural and physiological risk factors&lt;/p&gt;&lt;/div&gt;" /></Field><Field FieldID="153" OrdBy="710" ID="429" Name="Potential Harms" Type="text"><FieldValue Value="&lt;div class=&quot;content_para&quot;&gt;&lt;p&gt;Not stated&lt;/p&gt;&lt;/div&gt;" /></Field></Section><Section SecID="432" OrdBy="900" Name="Qualifying Statements"><Field FieldID="137" OrdBy="905" ID="433" Name="Qualifying Statements" Type="text"><FieldValue Value="&lt;ul style=&quot;list-style-type: disc;&quot;&gt;&#xD;&#xA;    &lt;li&gt;The information set out in this publication is current at the date of first publication and is intended for use as a guide of a general nature only and may or may not be relevant to particular patients or circumstances. Nor is this publication exhaustive of the subject matter. Persons implementing any recommendations contained in this publication must exercise their own independent skill or judgement or seek appropriate professional advice relevant to their own particular circumstances when so doing. Compliance with any recommendations cannot of itself guarantee discharge of the duty of care owed to patients and others coming into contact with the health professional and the premises from which the health professional operates. &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Whilst the text is directed to health professionals possessing appropriate qualifications and skills in ascertaining and discharging their professional (including legal) duties, it is not to be regarded as clinical advice and, in particular, is no substitute for a full examination and consideration of medical history in reaching a diagnosis and treatment based on accepted clinical practices. &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Accordingly, the Royal Australian College of General Practitioners and its employees and agents shall have no liability (including without limitation liability by reason of negligence) to any users of the information contained in this publication for any loss or damage (consequential or otherwise), cost or expense incurred or arising by reason of any person using or relying on the information contained in this publication and whether caused by reason of any error, negligent act, omission or misrepresentation in the information. &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;These guidelines have not included detailed information on the management of risk factors or early disease (e.g., what medications to use in treating hypertension). Similarly, they have not made recommendations about tertiary prevention (preventing complications in those with established disease). Also, information about prevention of infectious diseases has been limited largely to immunisation and some sexually transmitted infections (STIs). &lt;/li&gt;&#xD;&#xA;&lt;/ul&gt;" /></Field></Section><Section SecID="434" OrdBy="1000" Name="Implementation of the Guideline"><Field FieldID="131" OrdBy="1010" ID="436" Name="Description of Implementation Strategy" Type="text"><FieldValue Value="&lt;div class=&quot;content_para&quot;&gt;&lt;p&gt;For preventive care to be most effective, it needs to be planned, implemented and evaluated. Planning and engaging in preventive health is increasingly expected by patients. The Royal Australian College of General Practitioners (RACGP) thus provides the Red Book and &lt;em&gt;National guide to inform evidence-based guidelines&lt;/em&gt;, and the Green Book (see the &quot;Availability of Companion Documents&quot; field) to assist in development of programs of implementation. The RACGP is planning to introduce a small set of voluntary clinical indicators to enable practices to monitor their preventive activities.&lt;/p&gt;&lt;/div&gt;" /></Field><Field FieldID="117" OrdBy="1015" ID="437" Name="Implementation Tools" Type="picklist-many"><FieldValue Value="Chart Documentation/Checklists/Forms" /><FieldValue Value="Quick Reference Guides/Physician Guides" /><FieldValue Value="Resources" /></Field></Section><Section SecID="439" OrdBy="1100" Name="Institute of Medicine (IOM) National Healthcare Quality Report Categories"><Field FieldID="50" OrdBy="1105" ID="440" Name="IOM Care Need" Type="picklist-many"><FieldValue Value="Getting Better" /><FieldValue Value="Living with Illness" /><FieldValue Value="Staying Healthy" /></Field><Field FieldID="51" OrdBy="1110" ID="441" Name="IOM Domain" Type="picklist-many"><FieldValue Value="Effectiveness" /><FieldValue Value="Patient-centeredness" /></Field></Section><Section SecID="442" OrdBy="1200" Name="Identifying Information and Availability"><Field FieldID="97" OrdBy="1201" ID="392" Name="Bibliographic Source(s)" Type="citation"><FieldValue Value="&lt;table&gt;&lt;tr&gt;&lt;td&gt;Prevention of vascular and metabolic disease. In: Guidelines for preventive activities in general practice, 8th edition. East Melbourne (Australia): Royal Australian College of General Practitioners; 2012. p. 50-9.&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;" /></Field><Field FieldID="124" OrdBy="1205" ID="443" Name="Adaptation" Type="text"><FieldValue Value="&lt;div class=&quot;content_para&quot;&gt;&lt;p&gt;This guideline has been partially adapted from Australian, Canadian, United Kingdom, and/or United States preventive guidelines.&lt;/p&gt;&lt;/div&gt;" /></Field><Field FieldID="128" OrdBy="1215" ID="445" Name="Date Released" Type="text"><FieldValue Value="2012" /></Field><Field FieldID="158" OrdBy="1225" ID="447" Name="Guideline Developer(s)" Type="orglist-p"><FieldValue Value="Royal Australian College of General Practitioners - Professional Association" /></Field><Field FieldID="125" OrdBy="1235" ID="449" Name="Source(s) of Funding" Type="text"><FieldValue Value="&lt;div class=&quot;content_para&quot;&gt;&lt;p&gt;Royal Australian College of General Practitioners&lt;/p&gt;&lt;/div&gt;" /></Field><Field FieldID="126" OrdBy="1240" ID="450" Name="Guideline Committee" Type="text"><FieldValue Value="&lt;div class=&quot;content_para&quot;&gt;&lt;p&gt;Red Book Taskforce&lt;/p&gt;&lt;/div&gt;" /></Field><Field FieldID="127" OrdBy="1245" ID="451" Name="Composition of Group That Authored the Guideline" Type="text"><FieldValue Value="&lt;div class=&quot;content_para&quot;&gt;&lt;p&gt;&lt;em&gt;Taskforce Members&lt;/em&gt;: Dr Evan Ackermann (&lt;em&gt;Chair&lt;/em&gt;), Chair, National Standing Committee for Quality Care, RACGP; Professor Mark Harris, Centre for Primary Health Care and Equity, University of New South Wales, National Standing Committee for Quality Care, RACGP; Dr Karyn Alexander, General practitioner, Victoria; Dr Meredith Arcus, General practitioner, Western Australia; Linda Bailey, Project Manager, Red Book Taskforce; Dr John Bennett, Chair, National Standing Committee for e-Health, RACGP; Associate Professor Pauline Chiarelli, School of Health Sciences, University of Newcastle, New South Wales; Professor Chris Del Mar, Faculty of Health Sciences and Medicine, Bond University, Queensland; Professor Jon Emery, School of Primary, Aboriginal and Rural Health Care, The University of Western Australia, National Standing Committee for Research, RACGP; Dr Ben Ewald, School of Medicine and Public Health, University of Newcastle, New South Wales; Dr Dan Ewald, General practitioner, New South Wales, Adjunct Associate Professor, Northern Rivers University Centre for Rural Health, and Clinical Advisor North Coast NSW Medicare Local; Professor Michael Fasher, Adjunct Associate Professor, University of Sydney, and Conjoint Associate Professor, University of Western Sydney, New South Wales; Dr John Furler, Department of General Practice, The University of Melbourne, Victoria; Dr Faline Howes, General practitioner, Tasmania; Dr Caroline Johnson, Department of General Practice, The University of Melbourne, Victoria, National Standing Committee for Quality Care, RACGP; Dr Beres Joyner, General practitioner, Queensland; Associate Professor John Litt, Department of General Practice, Flinders University, South Australia, Deputy Chair, National Standing Committee for Quality Care, RACGP; Professor Danielle Mazza, Department of General Practice, School of Primary Care, Monash University, Victoria, National Standing Committee for Quality Care, RACGP; Professor Dimity Pond, School of Medicine and Public Health, University of Newcastle, New South Wales; Associate Professor Lena Sanci, Department of General Practice, The University of Melbourne, Victoria; Associate Professor Jane Smith, Faculty of Health Sciences and Medicine, Bond University, Queensland; Dr Tania Winzenberg, Deputy Chair, National Standing Committee for Research, RACGP&lt;/p&gt;&lt;/div&gt;" /></Field><Field FieldID="147" OrdBy="1250" ID="452" Name="Financial Disclosures/Conflicts of Interest" Type="text"><FieldValue Value="&lt;div class=&quot;content_para&quot;&gt;&lt;p&gt;Not stated&lt;/p&gt;&lt;/div&gt;" /></Field><Field FieldID="120" OrdBy="1256" ID="393" Name="Guideline Status" Type="text"><FieldValue Value="&lt;div class=&quot;content_para&quot;&gt;&lt;p&gt;This is the current release of the guideline.&lt;/p&gt;&lt;/div&gt;" /></Field><Field FieldID="118" OrdBy="1260" ID="454" Name="Guideline Availability" Type="text"><FieldValue Value="&lt;div class=&quot;content_para&quot;&gt;&lt;p&gt;Electronic copies: Available in Portable Document Format (PDF) from the &lt;a href=&quot;http://www.racgp.org.au/your-practice/guidelines/redbook/&quot; title=&quot;Royal Australian College of General Practitioners (RACGP) Web site&quot;&gt;Royal Australian College of General Practitioners (RACGP) Web site&lt;/a&gt;.&lt;/p&gt;&lt;/div&gt;" /></Field><Field FieldID="119" OrdBy="1265" ID="455" Name="Availability of Companion Documents" Type="text"><FieldValue Value="&lt;div class=&quot;content_para&quot;&gt;&lt;p&gt;The following are available:&lt;/p&gt;&#xD;&#xA;&lt;ul style=&quot;list-style-type: disc;&quot;&gt;&#xD;&#xA;    &lt;li&gt;Preventive activities over the lifecycle &amp;ndash; adults. Preventive activities over the lifecycle &amp;ndash; children. Electronic copies: Available in Portable Document Format (PDF) from the &lt;a href=&quot;http://www.racgp.org.au/download/Documents/Guidelines/Redbook8/redbook8_charts.pdf&quot; title=&quot;Royal Australian College of General Practitioners (RACGP) Web site&quot;&gt;Royal Australian College of General Practitioners (RACGP) Web site&lt;/a&gt;. &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Putting prevention into practice (green book). East Melbourne (Australia): Royal Australian College of General Practitioners; 2006. 104 p. Electronic copies: Available in PDF from the &lt;a href=&quot;http://www.racgp.org.au/your-practice/guidelines/greenbook/&quot; title=&quot;Royal Australian College of General Practitioners (RACGP) Web site&quot;&gt;RACGP Web site&lt;/a&gt;. &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;National guide to a preventive health assessment for Aboriginal and Torres Strait Islander people. East Melbourne (Australia): Royal Australian College of General Practitioners; 2012. 100 p. Electronic copies: Available in PDF from the &lt;a href=&quot;http://www.racgp.org.au/your-practice/guidelines/national-guide/&quot; title=&quot;Royal Australian College of General Practitioners (RACGP) Web site&quot;&gt;RACGP Web site&lt;/a&gt;. &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Supporting smoking cessation: a guide for health professionals. East Melbourne (Australia): Royal Australian College of General Practitioners; 2011. 80 p. Electronic copies: Available in PDF from the &lt;a href=&quot;http://www.racgp.org.au/your-practice/guidelines/smoking-cessation/&quot; title=&quot;Royal Australian College of General Practitioners (RACGP) Web site&quot;&gt;RACGP Web site&lt;/a&gt;. &lt;/li&gt;&#xD;&#xA;&lt;/ul&gt;&#xD;&#xA;&lt;p&gt;In addition, the appendices of the &lt;a href=&quot;http://www.racgp.org.au/your-practice/guidelines/redbook/&quot; title=&quot;Royal Australian College of General Practitioners (RACGP) Web site&quot;&gt;original guideline document&lt;/a&gt; provide the AUDIT-C assessment tool, the Australian Type 2 Diabetes Risk Assessment (AUSDRISK) assessment tool and the Australian cardiovascular risk charts.&lt;/p&gt;&lt;/div&gt;" /></Field><Field FieldID="143" OrdBy="1275" ID="457" Name="Patient Resources" Type="text"><FieldValue Value="&lt;div class=&quot;content_para&quot;&gt;&lt;p&gt;None available&lt;/p&gt;&lt;/div&gt;" /></Field><Field FieldID="142" OrdBy="1280" ID="458" Name="NGC Status" Type="text"><FieldValue Value="&lt;div class=&quot;content_para&quot;&gt;&lt;p&gt;This NGC summary was completed by ECRI Institute on May 31, 2013.&lt;/p&gt;&lt;/div&gt;" /></Field><Field FieldID="141" OrdBy="1290" ID="460" Name="Copyright Statement" Type="text"><FieldValue Value="&lt;div class=&quot;content_para&quot;&gt;&lt;p&gt;This NGC summary is based on the original guideline, which is subject to the guideline developer's copyright restrictions.&lt;/p&gt;&lt;/div&gt;" /></Field></Section><Section SecID="99999" OrdBy="99999" Name="Disclaimer"><Field FieldID="99999" OrdBy="99999" ID="99999" Name="NGC Disclaimer" Type="text"><FieldValue Value="&lt;p&gt;The National Guideline Clearinghouse (NGC) does not develop, produce, approve, or endorse the guidelines represented on this site.&lt;/p&gt; &#xD;&#xA;&lt;p&gt;All guidelines summarized by NGC and hosted on our site are produced under the auspices of medical specialty societies, relevant professional associations, public or private organizations, other government agencies, health care organizations or plans, and similar entities.&lt;/p&gt; &#xD;&#xA;&lt;p&gt;Guidelines represented on the NGC Web site are submitted by guideline developers, and are screened solely to determine that they meet the NGC Inclusion Criteria which may be found at &lt;a href=&quot;/about/inclusion-criteria.aspx&quot;&gt;http://www.guideline.gov/about/inclusion-criteria.aspx&lt;/a&gt;.&lt;/p&gt; &#xD;&#xA;&lt;p&gt;NGC, AHRQ, and its contractor ECRI Institute make no warranties concerning the content or clinical efficacy or effectiveness of the clinical practice guidelines and related materials represented on this site. Moreover, the views and opinions of developers or authors of guidelines represented on this site do not necessarily state or reflect those of NGC, AHRQ, or its contractor ECRI Institute, and inclusion or hosting of guidelines in NGC may not be used for advertising or commercial endorsement purposes.&lt;/p&gt; &#xD;&#xA;&lt;p&gt;Readers with questions regarding guideline content are directed to contact the guideline developer.&lt;/p&gt;" /></Field></Section></Version>
